[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 754
1. Kundu S, Fan K, Cao M, Lindner DJ, Zhao ZJ, Borden E, Yi T: Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents. J Immunol; 2010 Jun 01;184(11):6529-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Significantly, TPI-1 inhibited ( approximately 83%, p < 0.002) the growth of B16 melanoma tumors in mice at a tolerated oral dose in a T cell-dependent manner but had little effects on B16 cell growth in culture.
  • TPI-1 also inhibited B16 tumor growth and prolonged tumor mice survival as a tolerated s.c. agent.
  • In particular, analog TPI-1a4 as a tolerated oral agent completely inhibited the growth of K1735 melanoma tumors and was more effective than the parental lead against MC-26 colon cancer tumors in mice.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Soc Trans. 2006 Dec;34(Pt 6):1041-5 [17073746.001]
  • [Cites] Transpl Immunol. 2006 Dec;17(1):23-6 [17157209.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Aug;60(3):341-9 [17103170.001]
  • [Cites] J Exp Med. 1998 May 4;187(9):1417-26 [9565634.001]
  • [Cites] Immunopharmacology. 1998 Jun;39(3):255, 257 [9754911.001]
  • [Cites] J Biol Chem. 1998 Oct 16;273(42):27518-23 [9765283.001]
  • [Cites] J Biol Chem. 1998 Dec 18;273(51):33893-6 [9852037.001]
  • [Cites] Science. 1998 Dec 11;282(5396):2085-8 [9851930.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2105-16 [10561265.001]
  • [Cites] Curr Oncol Rep. 2008 Mar;10(2):114-21 [18377824.001]
  • [Cites] Immunol Rev. 2009 Mar;228(1):342-59 [19290938.001]
  • [Cites] Immunol Rev. 2009 May;229(1):67-87 [19426215.001]
  • [Cites] Cancer J. 2009 May-Jun;15(3):169-73 [19556898.001]
  • [Cites] J Interferon Cytokine Res. 2009 Aug;29(8):451-60 [19514839.001]
  • [Cites] J Immunol. 2009 Oct 15;183(8):4821-7 [19801506.001]
  • [Cites] J Struct Biol. 1997 Nov;120(2):201-3 [9417985.001]
  • [Cites] J Biol Chem. 1998 Feb 27;273(9):4904-8 [9478933.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3845-50 [9520455.001]
  • [Cites] Clin Immunol. 2001 Nov;101(2):113-29 [11683570.001]
  • [Cites] Science. 2001 Nov 9;294(5545):1343-6 [11598267.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):465-8 [11704759.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2002;42:209-34 [11807171.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Apr;13(2):95-109 [11900986.001]
  • [Cites] Med Oncol. 2001;18(3):197-207 [11917944.001]
  • [Cites] Am J Hum Genet. 2002 Jun;70(6):1555-63 [11992261.001]
  • [Cites] J Immunol. 2002 Nov 15;169(10):5978-85 [12421984.001]
  • [Cites] Oncol Res. 2003;13(6-10):347-52 [12725524.001]
  • [Cites] Trends Biochem Sci. 2003 Jun;28(6):284-93 [12826400.001]
  • [Cites] Clin Exp Metastasis. 2003;20(8):757-66 [14713109.001]
  • [Cites] Hum Mutat. 2004 Mar;23(3):267-77 [14974085.001]
  • [Cites] Oncogene. 2004 Mar 25;23(13):2347-56 [14743208.001]
  • [Cites] N Engl J Med. 2004 Apr 1;350(14):1461-3 [15070799.001]
  • [Cites] Oncologist. 2004;9(4):357-60 [15266089.001]
  • [Cites] Nat Med. 2004 Aug;10(8):849-57 [15273746.001]
  • [Cites] Nat New Biol. 1973 Apr 4;242(118):148-9 [4512654.001]
  • [Cites] Int J Cancer. 1977 May 15;19(5):621-6 [68013.001]
  • [Cites] J Natl Cancer Inst. 1979 Sep;63(3):541-8 [112311.001]
  • [Cites] Cancer Res. 1986 Apr;46(4 Pt 1):1612-6 [3004700.001]
  • [Cites] Rev Infect Dis. 1988 May-Jun;10(3):560-86 [3293160.001]
  • [Cites] Semin Oncol. 1988 Dec;15(6):500-11 [3061007.001]
  • [Cites] EMBO J. 1993 Jan;12(1):315-21 [8428589.001]
  • [Cites] Mol Cell Biol. 1993 Jun;13(6):3350-8 [7684496.001]
  • [Cites] Mol Cell Biol. 1993 Dec;13(12):7577-86 [8246974.001]
  • [Cites] J Immunol. 1995 Aug 1;155(3):1382-92 [7636203.001]
  • [Cites] Mol Cell Biol. 1995 Dec;15(12):7050-8 [8524272.001]
  • [Cites] Science. 1996 May 24;272(5265):1173-6 [8638162.001]
  • [Cites] J Med Chem. 1996 Jun 7;39(12):2285-92 [8691423.001]
  • [Cites] J Immunol. 1997 Feb 15;158(4):1565-71 [9029091.001]
  • [Cites] J Immunol Methods. 1997 May 12;204(1):57-66 [9202710.001]
  • [Cites] Exp Hematol. 1997 Jul;25(7):592-600 [9216734.001]
  • [Cites] Clin Cancer Res. 1997 Jun;3(6):931-7 [9815768.001]
  • [Cites] Annu Rev Immunol. 1999;17:875-904 [10358776.001]
  • [Cites] J Immunol. 2005 Jan 15;174(2):1013-9 [15634925.001]
  • [Cites] J Exp Med. 2005 Feb 7;201(3):361-71 [15699071.001]
  • [Cites] Eur J Med Genet. 2005 Apr-Jun;48(2):81-96 [16053901.001]
  • [Cites] J Immunol. 2005 Nov 15;175(10):7003-8 [16272361.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):326-34 [16507829.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2353s-2358s [16609058.001]
  • [Cites] Anticancer Res. 2006 Mar-Apr;26(2A):1113-34 [16619514.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2516-24 [16757724.001]
  • [Cites] Eur J Cancer. 2006 Jul;42(10):1351-6 [16740386.001]
  • [Cites] Curr Opin Chem Biol. 2006 Aug;10(4):357-61 [16814592.001]
  • [Cites] Curr Cancer Drug Targets. 2006 Sep;6(6):519-32 [17017875.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Nov;7(11):833-46 [17057753.001]
  • [Cites] Eur J Immunol. 1999 Dec;29(12):3887-97 [10601996.001]
  • [Cites] Cancer J Sci Am. 2000 Feb;6 Suppl 1:S2-7 [10685650.001]
  • [Cites] Cancer Gene Ther. 2000 Feb;7(2):207-14 [10770628.001]
  • [Cites] Semin Immunol. 2000 Aug;12(4):361-78 [10995583.001]
  • [Cites] J Biol Chem. 2001 Jun 22;276(25):23173-8 [11294838.001]
  • [Cites] J Immunol. 2001 Sep 15;167(6):3391-7 [11544330.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5280-9 [17875756.001]
  • [Cites] Clin Cancer Res. 2008 Mar 15;14(6):1905-12 [18347194.001]
  • [Cites] Nat Rev Cancer. 2008 Apr;8(4):299-308 [18354418.001]
  • (PMID = 20421638.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA095020-04; United States / NHLBI NIH HHS / HL / HL079441; United States / NHLBI NIH HHS / HL / R01 HL079441-04; United States / NCI NIH HHS / CA / R01 CA096636; United States / NCI NIH HHS / CA / CA095020; United States / NCI NIH HHS / CA / R01 CA089344-05; United States / NCI NIH HHS / CA / R01 CA095020; United States / NCI NIH HHS / CA / CA096636; United States / NCI NIH HHS / CA / R01 CA096636-05; United States / NCI NIH HHS / CA / CA0890344; United States / NHLBI NIH HHS / HL / R01 HL079441
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 6
  • [Other-IDs] NLM/ NIHMS190683; NLM/ PMC3049920
  •  go-up   go-down


2. Wu XZ, Zhang L, Shi BZ, Hu P: Inhibitory effects of N-(4-hydrophenyl) retinamide on liver cancer and malignant melanoma cells. World J Gastroenterol; 2005 Oct 7;11(37):5763-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory effects of N-(4-hydrophenyl) retinamide on liver cancer and malignant melanoma cells.
  • AIM: To investigate the effect of N-(4-hydrophenyl) retinamide (4-HPR), the derivative of retinoic acid, on inhibition of migration, invasion, cell growth, and induction of apoptosis in hepatocellular carcinoma cells (HCCs) and malignant melanoma cells.
  • RESULTS: We observed that the migration of HCC and melanoma cells was significantly suppressed by 4-HPR and the migration cells were reduced to 58+/-5.03 (control 201+/-27.2, P<0.05, n = 4) in SMMC 7721-k3 HCC, and to 254+/-25.04 (control 302+/-30.1, P<0.05, n = 4) in melanoma cells after 6-h incubation with 4-HPR.
  • The invasion through reconstituted basement membrane was also significantly reduced by 4-HPR treatment to 11.2+/-3.3 in SMMC 7721-k3 HCC (control 27+/-13.1), and to 24.3+/-3.2 in melanoma cells (control 67.5+/-10.1, P<0.05, n = 3).
  • Cell growth, especially in melanoma cells, was also significantly inhibited.
  • Furthermore, 3 micromol/L of 4-HPR induced apoptosis in B16 melanoma cells (37.11+/-0.94%) more significantly than all-trans retinoic acid (P<0.05), but it failed to induce apoptosis in SMMC 7721-k3 HCC.
  • The mechanism for 4-HPR-induced apoptosis was not clear, but we observed that 4-HPR could regulate p27(kip1), and overexpression of cerebroside sulfotransferase (CST) diminished the apoptosis induced by 4-HPR in melanoma cells.
  • CONCLUSION: 4-HPR is a potent inhibitor of HCC migration and inducer of melanoma cell apoptosis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Fenretinide / therapeutic use. Liver Neoplasms / drug therapy. Melanoma / drug therapy

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270382.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 187EJ7QEXL / Fenretinide; EC 2.8.2.- / Sulfotransferases; EC 2.8.2.11 / galactosylceramide sulfotransferase
  • [Other-IDs] NLM/ PMC4479673
  •  go-up   go-down


3. Patel D, Balderes P, Lahiji A, Melchior M, Ng S, Bassi R, Wu Y, Griffith H, Jimenez X, Ludwig DL, Hicklin DJ, Kang X: Generation and characterization of a therapeutic human antibody to melanoma antigen TYRP1. Hum Antibodies; 2007;16(3-4):127-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Generation and characterization of a therapeutic human antibody to melanoma antigen TYRP1.
  • TYRP1 (tyrosinase-related protein 1) is a melanoma antigen expressed in melanosomes and on the surface of melanoma cells.
  • Previous studies have shown that mouse antibodies to TYRP1 localized to melanomas in vivo and inhibited tumor growth and metastasis.
  • 20D7 recognized recombinant and native human TYRP1 by Western blotting and ELISA, and native TYRP1 in melanoma cells as determined by flow cytometry analysis.
  • 20D7 can bind to human and mouse Fc receptor and induce a strong ADCC response against human melanoma cells in vitro.
  • The antitumor activity of 20D7 was tested in human melanoma xenografts and mouse metastatic melanoma models in athymic nude mice.
  • Growth of s.c. human melanoma tumors and metastatic nodules of murine B16 tumor were significantly suppressed by 20D7 compared to human IgG control.
  • These results suggest that human anti-TYRP1 MAb may be a potent therapeutic for the treatment of malignant melanoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Melanoma, Experimental / therapy. Membrane Glycoproteins / immunology. Oxidoreductases / immunology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18334748.001).
  • [ISSN] 1093-2607
  • [Journal-full-title] Human antibodies
  • [ISO-abbreviation] Hum Antibodies
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Neoplasm; 0 / Membrane Glycoproteins; 9007-36-7 / Complement System Proteins; EC 1.- / Oxidoreductases; EC 1.14.18.- / TYRP1 protein, human
  •  go-up   go-down


Advertisement
4. Conacci-Sorrell M, Kaplan A, Raveh S, Gavert N, Sakurai T, Ben-Ze'ev A: The shed ectodomain of Nr-CAM stimulates cell proliferation and motility, and confers cell transformation. Cancer Res; 2005 Dec 15;65(24):11605-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nr-CAM, a cell-cell adhesion molecule of the immunoglobulin-like cell adhesion molecule family, known for its function in neuronal outgrowth and guidance, was recently identified as a target gene of beta-catenin signaling in human melanoma and colon carcinoma cells and tissue.
  • We detected a metalloprotease-mediated shedding of Nr-CAM into the culture medium of cells transfected with Nr-CAM, and of endogenous Nr-CAM in B16 melanoma cells.
  • Moreover, Nr-CAM was found in complex with alpha4beta1 integrins in melanoma cells, indicating that it can mediate, in addition to homophilic cell-cell adhesion, heterophilic adhesion with extracellular matrix receptors.
  • Suppression of Nr-CAM levels by small interfering RNA in B16 melanoma inhibited the adhesive and tumorigenic capacities of these cells.
  • [MeSH-major] Cell Adhesion Molecules / metabolism. Cell Movement. Cell Proliferation. Cell Transformation, Neoplastic. Melanoma, Experimental / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357171.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / Culture Media, Conditioned; 0 / Enzyme Inhibitors; 0 / Integrin alpha4beta1; 0 / NRCAM protein, human; 0 / Nrcam protein, mouse; 0 / RNA, Small Interfering; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.4.- / Metalloproteases
  •  go-up   go-down


5. Iwai Y, Terawaki S, Honjo T: PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol; 2005 Feb;17(2):133-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we report that hematogenous spread of poorly immunogenic B16 melanoma cells to the liver was inhibited in PD-1-deficient mice.
  • As compared with wild-type mice, intrasplenic injection of B16 cells into PD-1-deficient mice showed enhanced induction of effector T cells in spleen, prolonged T cell proliferation and cytokine production, and augmented homing of effector T cells to tumor sites in the liver, resulting in accumulation of effector T cells in the tumor sites.
  • PD-1 blockade by genetic manipulation or antibody treatment inhibited not only hematogenous dissemination of B16 melanoma cells to the liver on the C57BL/6 background, but also dissemination of CT26 colon cancer cells to the lung on the BALB/c background.
  • [MeSH-major] Antigens, Surface / genetics. Antigens, Surface / physiology. Melanoma, Experimental / immunology. T-Lymphocytes, Cytotoxic / immunology

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15611321.001).
  • [ISSN] 0953-8178
  • [Journal-full-title] International immunology
  • [ISO-abbreviation] Int. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Apoptosis Regulatory Proteins; 0 / Cytokines; 0 / Pdcd1 protein, mouse; 0 / Programmed Cell Death 1 Receptor
  •  go-up   go-down


6. Alshamsan A, Hamdy S, Samuel J, El-Kadi AO, Lavasanifar A, Uludağ H: The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine. Biomaterials; 2010 Feb;31(6):1420-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine.
  • In this study, we investigated the potential of nanoparticles based on polyethylenimine (PEI) modified with stearic acid (StA), to deliver siRNA for efficient STAT3 downregulation in B16 melanoma cells.
  • The B16 cells were targeted with approximately 6-200 nm of siRNA complexes for 36 h.
  • Compared to the PEI complexes, the PEI-StA complexes showed higher potency in STAT3 silencing in B16 cells accompanied by a significant induction of IL-6 secretion and a reduction of VEGF production.
  • When the cells were treated with 50 nm of siRNA complexes on a daily basis, the cell viability was dramatically reduced reaching only to 16% after the third daily dose of PEI-StA complexes, as compared to the 69% viability observed with the PEI complexes at an equivalent time period.
  • [MeSH-major] Apoptosis / drug effects. Lipids / chemistry. Melanoma / genetics. Melanoma / therapy. Polyethyleneimine / chemistry. RNA, Small Interfering / administration & dosage. RNA, Small Interfering / genetics. STAT3 Transcription Factor / genetics

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19913908.001).
  • [ISSN] 1878-5905
  • [Journal-full-title] Biomaterials
  • [ISO-abbreviation] Biomaterials
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / / MOP 42407; Canada / Canadian Institutes of Health Research / / MOP 74452
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Lipids; 0 / RNA, Small Interfering; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 9002-98-6 / Polyethyleneimine
  •  go-up   go-down


7. Chen P, Jiang X, Wei DP, Li L: [The effects of intense pulsed light and 5-aminolevulinic acid on the cultured B16 marine melanoma cells]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Mar;41(2):280-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The effects of intense pulsed light and 5-aminolevulinic acid on the cultured B16 marine melanoma cells].
  • OBJECTIVE: To investigate the effects of IPL and IPL plus 5-ALA on the proliferation, melanogenesis and tyrosinase activity of cultured B16 murine melanoma cells.
  • METHODS: B16 cells were pretreated with or without ALA and irradiated with IPL (20, 30, 40 J/cm2), also the negative control group and the positive control UVA irradiation group (3, 4, 5 J/cm2) were designed.
  • The proliferation of the treated B16 cells were evaluated with MTT method, the melanogenesis of the cells was tested with NaOH assay as well as tyrosinase activity was detected at 1 d, 2 d, 3 d, 4 d, and 5 d after irradiation.
  • RESULTS: 5 mmol/L 5-ALA did not affect the proliferation, melanogenesis and tyrosinase activity in B16 melanoma cell.
  • The cell yielding in UVA group increased significantly (P < 0.05) compared with that of negative control group after UVA irradiation (3, 4 J/cm2), but the proliferation of the treated B16 cells were suppressed after UVA irradiation (5 J/cm2).
  • IPL or IPL plus ALA have inhibitory effects on melanogenesis without any influence on cell tyrosinase activity in B16 cells.
  • CONCLUSIONS: We demonstrated that UVA could stimulate the proliferation of B16 cells, increase the melanogenesis and tyrosinase activity of the cells.
  • IPL or IPL plus ALA have inhibitory effects on melanogenesis without any influence on cell proliferation and tyrosinase activity in B16 cells.
  • [MeSH-major] Aminolevulinic Acid / pharmacology. Melanoma, Experimental / pathology. Photochemotherapy / methods. Photosensitizing Agents / pharmacology. Ultraviolet Rays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20506653.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Melanins; 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


8. Bettahi I, Dasgupta G, Renaudet O, Chentoufi AA, Zhang X, Carpenter D, Yoon S, Dumy P, BenMohamed L: Antitumor activity of a self-adjuvanting glyco-lipopeptide vaccine bearing B cell, CD4+ and CD8+ T cell epitopes. Cancer Immunol Immunother; 2009 Feb;58(2):187-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we explored a self-adjuvanting glyco-lipopeptide (GLP) as a platform for cancer vaccines using as a model MO5, an OVA-expressing mouse B16 melanoma.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18584174.001).
  • [ISSN] 1432-0851
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / EY14900; United States / NEI NIH HHS / EY / EY16663
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Cancer Vaccines; 0 / Epitopes, T-Lymphocyte; 0 / Glycolipids; 0 / Lipopeptides; 82115-62-6 / Interferon-gamma; 9006-59-1 / Ovalbumin; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse
  •  go-up   go-down


9. Wang JF, Su RB, Wu N, Xu B, Lu XQ, Liu Y, Li J: Inhibitory effect of agmatine on proliferation of tumor cells by modulation of polyamine metabolism. Acta Pharmacol Sin; 2005 May;26(5):616-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Similar results were obtained in the transplanted B16 melanoma tumor model.
  • [MeSH-minor] Animals. Cell Line, Tumor. Humans. L-Lactate Dehydrogenase / metabolism. Male. Melanoma, Experimental / pathology. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Neoplasm Transplantation. Putrescine / pharmacology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Putrescine .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842783.001).
  • [ISSN] 1671-4083
  • [Journal-full-title] Acta pharmacologica Sinica
  • [ISO-abbreviation] Acta Pharmacol. Sin.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Polyamines; 70J407ZL5Q / Agmatine; EC 1.1.1.27 / L-Lactate Dehydrogenase; V10TVZ52E4 / Putrescine
  •  go-up   go-down


10. Arora A, Su G, Mathiowitz E, Reineke J, Chang AE, Sabel MS: Neoadjuvant intratumoral cytokine-loaded microspheres are superior to postoperative autologous cellular vaccines in generating systemic anti-tumor immunity. J Surg Oncol; 2006 Oct 1;94(5):403-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: C57BL6 mice with established B16 melanomas underwent a single intralesional injection of IL-12, TNF-alpha or GM-CSF PLAM, alone or in combination.
  • Adjuvant therapy, using irradiated B16 cells in combination with equivalent doses of IL-12 and TNF-alpha, failed to generate a similar T-cell response or prevent re-challenge.
  • [MeSH-major] Cancer Vaccines / administration & dosage. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Immunotherapy, Adoptive. Interleukin-12 / administration & dosage. Melanoma, Experimental / immunology. Melanoma, Experimental / therapy. Tumor Necrosis Factor-alpha / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16967445.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA102602-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Polymers; 0 / Tumor Necrosis Factor-alpha; 187348-17-0 / Interleukin-12; 26100-51-6 / poly(lactic acid); 33X04XA5AT / Lactic Acid; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


11. Hao S, Ye Z, Li F, Meng Q, Qureshi M, Yang J, Xiang J: Epigenetic transfer of metastatic activity by uptake of highly metastatic B16 melanoma cell-released exosomes. Exp Oncol; 2006 Jun;28(2):126-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic transfer of metastatic activity by uptake of highly metastatic B16 melanoma cell-released exosomes.
  • METHODS: The highly metastatic B16 melanoma cell line (BL6-10) was generated in our laboratory.
  • For phenotypic analysis BL6-10 and F1 melanoma cells were stained with FITC-conjugated anti-MHC I (H-2K(b)), MHC II (Ia(b)) and Met 72 antibodies and analyzed by flow cytometry.
  • C57BL/6 mice (8 per group) were injected (i. v.) with 0.5 x 10(6) F1, BL6-10 and F1(EXO) melanoma cells.
  • All mice inoculated with BL6-10 melanoma cells had numerous lung tumor colonies, while mice injected with F1 tumor cells were free of lung metastatic colonies.
  • [MeSH-major] Cytoplasmic Vesicles / transplantation. Lung Neoplasms / secondary. Melanoma, Experimental / pathology. Skin Neoplasms / pathology


12. Mac Keon S, Gazzaniga S, Mallerman J, Bravo AI, Mordoh J, Wainstok R: Vaccination with dendritic cells charged with apoptotic/necrotic B16 melanoma induces the formation of subcutaneous lymphoid tissue. Vaccine; 2010 Nov 29;28(51):8162-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaccination with dendritic cells charged with apoptotic/necrotic B16 melanoma induces the formation of subcutaneous lymphoid tissue.
  • Mice vaccinated with DC charged with apoptotic/necrotic B16 cells (DC-Apo/Nec) are protected against B16 challenge.
  • [MeSH-major] Cancer Vaccines / immunology. Dendritic Cells / immunology. Lymphoid Tissue / physiology. Melanoma, Experimental / immunology. Melanoma, Experimental / prevention & control. Vaccination / methods

  • MedlinePlus Health Information. consumer health - Immunization.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20937314.001).
  • [ISSN] 1873-2518
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines
  •  go-up   go-down


13. Chen L, Zhang S, Li X, Sun B, Zhao X, Zhang D, Zhao S: A pilot study of vasculogenic mimicry immunohistochemical expression in intraocular melanoma model. Oncol Rep; 2009 Apr;21(4):989-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study of vasculogenic mimicry immunohistochemical expression in intraocular melanoma model.
  • However, some previous studies have demonstrated the absence of VM channel in a uveal melanoma xenograft mice model.
  • C57Bl/6 mice were randomly divided into 3 groups used for the blood supply models of malignant melanoma.
  • The right eyes of the mice received subretinal injections with B16 melanoma cells and the left eyes were the control.
  • [MeSH-major] Eye Neoplasms / blood supply. Melanoma, Experimental / blood supply

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287998.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


14. Lutterbuese P, Brischwein K, Hofmeister R, Crommer S, Lorenczewski G, Petersen L, Lippold S, da Silva A, Locher M, Baeuerle PA, Schlereth B: Exchanging human Fcgamma1 with murine Fcgamma2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model. Cancer Immunol Immunother; 2007 Apr;56(4):459-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The anti-tumor activities of adecatumumab and mu-adecatumumab were then compared side-by-side in a lung metastasis mouse model established with a syngeneic B16 melanoma line expressing human EpCAM at physiologically relevant levels.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16937114.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / FCGR1A protein, human; 0 / Fc gamma receptor IIA; 0 / MT201 antibody, human; 0 / Receptors, IgG
  •  go-up   go-down


15. Sano H, Leboeuf JP, Novitskiy SV, Seo S, Zaja-Milatovic S, Dikov MM, Kume T: The Foxc2 transcription factor regulates tumor angiogenesis. Biochem Biophys Res Commun; 2010 Feb 5;392(2):201-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we show that FoxC2 is highly expressed in human breast and colonic tumors and in the tumor endothelium in human and mouse melanomas.
  • Using the B16 melanoma tumor model, we investigated the function of Foxc2 in tumor angiogenesis.
  • After subcutaneous injection of B16 melanoma cells, primary tumor growth as well as neovascularization was markedly reduced in mice lacking one copy of the Foxc2 gene (Foxc2+/-).
  • Consistently, expression levels of several angiogenic factors, including vascular endothelial growth factor (Vegf), matrix metallopeptidase 2 (Mmp2), and platelet-derived growth factor-B (Pdgfb), were significantly decreased in B16 tumors grown in Foxc2+/- mice, and tumor blood vessels formed in Foxc2+/- mice showed reduced coverage of mural cells and endothelial cell apoptosis.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7358-67 [17671206.001]
  • [Cites] Trends Cardiovasc Med. 2008 Aug;18(6):224-8 [19185813.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8293-300 [17804744.001]
  • [Cites] Nat Rev Cancer. 2007 Nov;7(11):847-59 [17943136.001]
  • [Cites] Genes Dev. 2008 May 15;22(10):1276-312 [18483217.001]
  • [Cites] Ann N Y Acad Sci. 2008;1131:225-34 [18519975.001]
  • [Cites] PLoS One. 2008;3(6):e2401 [18545664.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10185-90 [18632559.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):579-91 [18596824.001]
  • [Cites] J Biol Chem. 2008 Aug 29;283(35):23791-800 [18579532.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):249-57 [11001068.001]
  • [Cites] Genes Dev. 2001 Sep 15;15(18):2470-82 [11562355.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):135-43 [12107098.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1083-93 [12651601.001]
  • [Cites] Nat Med. 2003 Jun;9(6):713-25 [12778170.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5224-9 [14500349.001]
  • [Cites] FASEB J. 2004 Feb;18(2):338-40 [14657001.001]
  • [Cites] Nat Med. 2004 Sep;10(9):974-81 [15322537.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Development. 1997 Nov;124(22):4627-38 [9409679.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):1048-51 [9500469.001]
  • [Cites] Cell. 1998 Sep 18;94(6):715-25 [9753319.001]
  • [Cites] Dev Biol. 1999 Sep 15;213(2):418-31 [10479458.001]
  • [Cites] Nat Cell Biol. 2005 Sep;7(9):870-9 [16113679.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):967-74 [16355214.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1280-9 [16731761.001]
  • [Cites] Dev Biol. 2006 Jun 15;294(2):458-70 [16678147.001]
  • [Cites] Nat Rev Cancer. 2007 May;7(5):327-31 [17457300.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4311-9 [17483344.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10069-74 [17537911.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8733-42 [18974115.001]
  • [Cites] Cell. 2007 Aug 24;130(4):691-703 [17719546.001]
  • (PMID = 20060810.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL074121-03; United States / NHLBI NIH HHS / HL / HL74121; United States / NHLBI NIH HHS / HL / R01 HL074121-03; United States / NCI NIH HHS / CA / R01 CA100562; United States / NHLBI NIH HHS / HL / R01 HL074121; United States / NHLBI NIH HHS / HL / HL074121-02; United States / NCI NIH HHS / CA / CA100562; United States / NEI NIH HHS / EY / R01 EY019484; United States / NHLBI NIH HHS / HL / R01 HL074121-02; United States / NHLBI NIH HHS / HL / R01 HL074121-04; United States / NHLBI NIH HHS / HL / HL074121-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Forkhead Transcription Factors; 0 / Vascular Endothelial Growth Factor A; 0 / mesenchyme fork head 1 protein; EC 3.4.24.24 / Matrix Metalloproteinase 2
  • [Other-IDs] NLM/ NIHMS169896; NLM/ PMC2822046
  •  go-up   go-down


16. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H: IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med; 2009 Jul 6;206(7):1457-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We show that growth of B16 melanoma and MB49 bladder carcinoma is reduced in IL-17(-/-) mice but drastically accelerated in IFN-gamma(-/-) mice, contributed to by elevated intratumoral IL-17, indicating a role of IL-17 in promoting tumor growth.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 May 15;19(21):2548-56 [10851053.001]
  • [Cites] Nat Immunol. 2007 Apr;8(4):369-77 [17351619.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2620-7 [12411307.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61 [9636188.001]
  • [Cites] Cell. 1999 Aug 6;98(3):295-303 [10458605.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9113-6 [16230363.001]
  • [Cites] J Immunol. 2005 Nov 1;175(9):6177-89 [16237115.001]
  • [Cites] Nat Immunol. 2005 Nov;6(11):1123-32 [16200070.001]
  • [Cites] Nat Med. 2005 Dec;11(12):1314-21 [16288283.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 23;103(21):8137-42 [16698929.001]
  • [Cites] Immunity. 2006 Jun;24(6):677-88 [16782025.001]
  • [Cites] Nature. 2006 Jul 27;442(7101):461-5 [16688182.001]
  • [Cites] Nat Rev Immunol. 2006 Nov;6(11):836-48 [17063185.001]
  • [Cites] Nat Rev Immunol. 2007 Jan;7(1):41-51 [17186030.001]
  • [Cites] Nat Immunol. 2007 Apr;8(4):345-50 [17375096.001]
  • [Cites] Annu Rev Immunol. 2007;25:821-52 [17201677.001]
  • [Cites] J Immunol. 2007 Oct 1;179(7):4313-7 [17878325.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3915-23 [18483277.001]
  • [Cites] Clin Cancer Res. 2008 Jun 1;14(11):3254-61 [18519750.001]
  • [Cites] Blood. 2008 Jul 15;112(2):362-73 [18354038.001]
  • [Cites] Immunol Res. 2008;41(2):87-102 [18172584.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Sep 26;374(3):533-7 [18655770.001]
  • [Cites] Blood. 2008 Sep 1;112(5):2101-10 [18596226.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15505-10 [18832156.001]
  • [Cites] Immunity. 2008 Oct 17;29(4):628-36 [18848474.001]
  • [Cites] Cancer Cell. 2009 Feb 3;15(2):114-23 [19185846.001]
  • [Cites] Cancer Res. 2009 Mar 1;69(5):2010-7 [19244111.001]
  • [Cites] J Hepatol. 2009 May;50(5):980-9 [19329213.001]
  • [Cites] Blood. 2009 Jul 9;114(2):357-9 [19289853.001]
  • [Cites] Immunity. 2002 Sep;17(3):375-87 [12354389.001]
  • (PMID = 19564351.001).
  • [ISSN] 1540-9538
  • [Journal-full-title] The Journal of experimental medicine
  • [ISO-abbreviation] J. Exp. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01CA115815; United States / NIAID NIH HHS / AI / R01 AI066008; United States / NCI NIH HHS / CA / R01CA122976; United States / NCI NIH HHS / CA / R01 CA122976; United States / NCI NIH HHS / CA / R01 CA115815
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-17; 0 / Interleukin-6; 0 / STAT3 Transcription Factor; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2715087
  •  go-up   go-down


17. Chen X, Wang X, Wang Y, Yang L, Hu J, Xiao W, Fu A, Cai L, Li X, Ye X, Liu Y, Wu W, Shao X, Mao Y, Wei Y, Chen L: Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. J Control Release; 2010 Jul 1;145(1):17-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Then we characterized the tbFGF-modified liposome (tbFGF-LPs) and examined internalization of doxorubicin in tumor cells (TRAMP-C1, B16) and HUVEC cells in vitro.
  • In vivo, we evaluated the biodistribution and antitumor efficacy of tbFGF-LPs-DOX and tbFGF-LPs-PTX in C57BL/6J mice bearing TRAMP-C1 prostate carcinoma and B16 melanoma, respectively.
  • The tbFGF-LPs-DOX significantly improved the uptake of doxorubicin in TRAMP-C1, B16 and HUVEC cells, respectively.
  • Biodistribution study in B16 tumor-bearing mice showed that tbFGF-LPs-PTX achieved 7.1-fold (72.827+/-7.321mgh/L vs 10.292+/-0.775mgh/L, mean+/-SD, P<0.01) accumulation of paclitaxel in tumor tissue than those of free paclitaxel.
  • More importantly, treatment of tumor-bearing mice with tbFGF-LPs-DOX and tbFGF-LPs-PTX showed the significant inhibition in tumor growth and improvement in survival rate as compared with mice treated with free and liposomal drugs in TRAMP-C1 and B16 tumor models, respectively.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Drug Carriers / chemistry. Fibroblast Growth Factor 2 / chemistry. Melanoma, Experimental / drug therapy. Prostatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20307599.001).
  • [ISSN] 1873-4995
  • [Journal-full-title] Journal of controlled release : official journal of the Controlled Release Society
  • [ISO-abbreviation] J Control Release
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cations; 0 / Drug Carriers; 0 / Liposomes; 0 / Receptors, Fibroblast Growth Factor; 103107-01-3 / Fibroblast Growth Factor 2; 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


18. Rodríguez-Cuesta J, Hernando FL, Mendoza L, Gallot N, de Cerio AA, Martínez-de-Tejada G, Vidal-Vanaclocha F: Candida albicans enhances experimental hepatic melanoma metastasis. Clin Exp Metastasis; 2010;27(1):35-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Candida albicans enhances experimental hepatic melanoma metastasis.
  • In this study, a well-established model of IL-18-dependent hepatic melanoma metastasis was used to study whether C. albicans can alter the ability of murine B16 melanoma (B16M) cells to colonize the liver.
  • [MeSH-major] Candidiasis / complications. Liver Neoplasms, Experimental / microbiology. Liver Neoplasms, Experimental / secondary. Melanoma, Experimental / microbiology. Melanoma, Experimental / secondary

  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • Hazardous Substances Data Bank. KETOCONAZOLE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Biotechnol. 1993 Dec;4(6):727-33 [7764472.001]
  • [Cites] Cancer Metastasis Rev. 2006 Sep;25(3):307-13 [17029030.001]
  • [Cites] Environ Mol Mutagen. 2005 Mar-Apr;45(2-3):284-303 [15744742.001]
  • [Cites] Infect Immun. 2002 Jun;70(6):3284-6 [12011026.001]
  • [Cites] Int J Cancer. 2006 Jun 15;118(12):3030-44 [16404738.001]
  • [Cites] Hepatology. 2001 Aug;34(2):298-310 [11481615.001]
  • [Cites] Cancer Res. 1993 Oct 15;53(20):5051-4 [8267795.001]
  • [Cites] Am J Med. 2002 Apr 1;112(5):380-5 [11904112.001]
  • [Cites] Med Mycol. 2004 Dec;42(6):485-98 [15682636.001]
  • [Cites] Eur J Immunol. 2003 Dec;33(12):3409-17 [14635050.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):734-9 [10639148.001]
  • [Cites] Clin Exp Metastasis. 2005;22(7):549-58 [16475025.001]
  • [Cites] Vet Immunol Immunopathol. 2003 Jan 10;91(1):1-12 [12507844.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1068-75 [16885047.001]
  • [Cites] FEMS Immunol Med Microbiol. 1999 Apr;23(4):343-54 [10225294.001]
  • [Cites] Infect Immun. 2000 Mar;68(3):1134-41 [10678917.001]
  • [Cites] Cancer Res. 2003 Jan 15;63(2):491-7 [12543807.001]
  • [Cites] J Infect. 2005 Jun;50(5):443-9 [15907554.001]
  • [Cites] J Natl Cancer Inst. 1997 May 7;89(9):645-51 [9150189.001]
  • [Cites] Nat Rev Cancer. 2006 Jun;6(6):449-58 [16723991.001]
  • [Cites] Cancer Res. 1994 May 15;54(10):2667-72 [8168095.001]
  • [Cites] Adv Cancer Res. 1990;54:159-211 [1688681.001]
  • [Cites] Cancer Metastasis Rev. 2006 Sep;25(3):417-34 [17001512.001]
  • (PMID = 20035374.001).
  • [ISSN] 1573-7276
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Inflammation Mediators; 0 / Interleukin-18; 0 / Tumor Necrosis Factor-alpha; R9400W927I / Ketoconazole
  •  go-up   go-down


19. Umeshappa CS, Huang H, Xie Y, Wei Y, Mulligan SJ, Deng Y, Xiang J: CD4+ Th-APC with acquired peptide/MHC class I and II complexes stimulate type 1 helper CD4+ and central memory CD8+ T cell responses. J Immunol; 2009 Jan 1;182(1):193-206
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD4(+) Th-APC with acquired pMHC II and I were capable of stimulating CD4(+) Th1 and central memory CD8(+)44(+)CD62L(high)IL-7R(+) T cell responses leading to antitumor immunity against OVA-expressing mouse B16 melanoma.
  • [MeSH-minor] Amino Acid Sequence. Animals. Antigens, CD44 / biosynthesis. Cell Line, Tumor. Cytotoxicity Tests, Immunologic. L-Selectin / biosynthesis. Melanoma, Experimental. Mice. Mice, Inbred C57BL. Mice, Knockout. Mice, Transgenic. Molecular Sequence Data. Receptors, Interleukin-7 / biosynthesis

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19109150.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Histocompatibility Antigens Class I; 0 / Histocompatibility Antigens Class II; 0 / Peptide Fragments; 0 / Receptors, Interleukin-7; 126880-86-2 / L-Selectin
  •  go-up   go-down


21. Seledtsov VI, Niza NA, Felde MA, Shishkov AA, Samarin DM, Seledtsova GV, Seledtsov DV: Xenovaccinotherapy for colorectal cancer. Biomed Pharmacother; 2007 Feb-Apr;61(2-3):125-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objectives of this phase I-II trial were to assess the toxicity, immunological and clinical responses induced in 37 patients with stage IV colorectal cancer by the subcutaneous administration of a xenogenic polyantigenic vaccine (XPV) prepared from disrupted murine melanoma (B16) and carcinoma (LLC) cells.
  • A significant increase in cell-mediated immunoreactivity to both LLC and B16 antigens (Ags) occurred in the patients after inducing vaccinations, as determined by delayed-type hypersensitivity (DTH) skin reactions, as well as by blood lymphocyte proliferation responses.
  • [MeSH-minor] Adult. Aged. Animals. Antineoplastic Agents / therapeutic use. Carcinoma. Drug Synergism. Female. Humans. Immunity, Cellular / drug effects. Immunoglobulin G / drug effects. Immunoglobulin G / metabolism. Injections, Subcutaneous. Interferon-gamma / blood. Interferon-gamma / drug effects. Interleukin-4 / blood. Male. Melanoma. Mice. Middle Aged. Neoplasm Staging. Survival Analysis. Th1 Cells / drug effects. Th1 Cells / metabolism. Th2 Cells / drug effects. Th2 Cells / metabolism. Vaccination

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17258887.001).
  • [ISSN] 0753-3322
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Cancer Vaccines; 0 / Immunoglobulin G; 0 / Interleukin-2; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


22. Ouyang GF, Saio M, Suwa T, Imai H, Nakagawa J, Nonaka K, Umemura N, Kijima M, Takami T: Interleukin-2 augmented activation of tumor associated macrophage plays the main role in MHC class I in vivo induction in tumor cells that are MHC negative in vitro. Int J Oncol; 2006 May;28(5):1201-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we utilized Interleukin-2 (IL-2) cDNA-introduced B16 melanoma cells (B16/IL-2) and vehicle-alone control cells (B16/mock) to examine whether TAM could contribute to the induction of MHC class I on B16 cells in vivo.
  • Interestingly, although B16/mock and B16/IL-2 did not express MHC class I in vitro, MHC class I was strongly expressed in vivo in B16/IL-2 in comparison to B16/mock.
  • Although in vivo treatment of anti-NK1.1 antibody abolished MHC expression in B16/mock in vivo, the same treatment did not influence MHC expression in B16/IL-2.
  • Interestingly, both anti-asialo GM1 and anti-CD11b treatment strongly decreased MHC expression in B16/IL-2.
  • TAM expressed both asialo GM1 and CD11b antigen, and TAM recovered from B16/IL-2 produced interferon gamma (IFNgamma) 6 times more than that from B16/mock.
  • In addition, TAM recovered from B16/IL-2 secreted 33.64 times more IFNgamma in response to in vitro administration of IL-2.
  • TAM recovered from IL-2 expressed middle affinity receptor of IL-2 (CD122 and CD132) while that from B16/mock expressed low affinity receptor (CD25 and CD132).
  • Finally, we observed that B16 cells became apoptotic with IFNgamma treatment in vitro.
  • [MeSH-major] Histocompatibility Antigens Class I / genetics. Interleukin-2 / pharmacology. Macrophages / immunology. Melanoma, Experimental / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596236.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Histocompatibility Antigens Class I; 0 / Interleukin-2
  •  go-up   go-down


23. Kai H, Baba M, Okuyama T: Inhibitory effect of Cucumis sativus on melanin production in melanoma B16 cells by downregulation of tyrosinase expression. Planta Med; 2008 Dec;74(15):1785-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibitory effect of Cucumis sativus on melanin production in melanoma B16 cells by downregulation of tyrosinase expression.
  • MeOH extracts of leaves and stems inhibited melanin production in B16 cells.
  • These extracts did not affect the activity of mushroom tyrosinase or crude enzyme lysate from B16 cells.
  • [MeSH-major] Cucumis sativus. Melanins / biosynthesis. Melanoma, Experimental / metabolism. Monophenol Monooxygenase / metabolism. Plant Extracts / pharmacology

  • Hazardous Substances Data Bank. KOJIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19009501.001).
  • [ISSN] 0032-0943
  • [Journal-full-title] Planta medica
  • [ISO-abbreviation] Planta Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Melanins; 0 / Plant Extracts; 0 / Pyrones; 6K23F1TT52 / kojic acid; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


24. Guo RR, Liu Y, Lu WL, Zhao JH, Wang XQ, Zhang H, Wang JC, Zhang X, Zhang Q: A recombinant peptide, hirudin, potentiates the inhibitory effects of stealthy liposomal vinblastine on the growth and metastasis of melanoma. Biol Pharm Bull; 2008 Apr;31(4):696-702
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A recombinant peptide, hirudin, potentiates the inhibitory effects of stealthy liposomal vinblastine on the growth and metastasis of melanoma.
  • In vitro cytotoxicity, cell adhesion to extracellular matrix (ECM) proteins, and cell invasion and migration assays were performed on human A375 melanoma cell line.
  • Furthermore, administered at the initial implantation of murine B16 melanoma cells, hirudin evidently delayed the growth of tumor, and depressed the occurrence of experimental lung metastasis.
  • In conclusion, administration of recombinant hirudin followed by giving stealthy liposomal vinblastine may be beneficial for inhibiting the growth and metastasis of melanoma in vivo.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Hirudins / pharmacology. Melanoma / drug therapy. Protease Inhibitors / pharmacology. Vinblastine / pharmacology
  • [MeSH-minor] Animals. Cell Adhesion / drug effects. Cell Line, Tumor. Cell Movement / drug effects. Drug Carriers. Drug Screening Assays, Antitumor. Drug Synergism. Extracellular Matrix Proteins / chemistry. Homeostasis / drug effects. Humans. Liposomes. Male. Melanoma, Experimental / drug therapy. Mice. Mice, Inbred BALB C. Neoplasm Invasiveness / prevention & control. Neoplasm Metastasis / prevention & control. Particle Size. Recombinant Proteins / pharmacology. Tetrazolium Salts. Thiazoles

  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379065.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Carriers; 0 / Extracellular Matrix Proteins; 0 / Hirudins; 0 / Liposomes; 0 / Protease Inhibitors; 0 / Recombinant Proteins; 0 / Tetrazolium Salts; 0 / Thiazoles; 298-93-1 / thiazolyl blue; 5V9KLZ54CY / Vinblastine
  •  go-up   go-down


25. Mousa SA, Linhardt R, Francis JL, Amirkhosravi A: Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb Haemost; 2006 Dec;96(6):816-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using the B16 melanoma mouse model of metastasis, subcutaneous (s.c.) injection of NA-LMWH or enoxaparin (10 mg/kg), three hours before intravenous (i.v.) injection of metastatic melanoma cells, followed by daily doses for 14 days, reduced lung tumor formation by 70% (P < 0.001). I.v. injection of tumor cells resulted in a significant (50-62%, P < 0.01) fall in platelet counts.

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Thromb Hemost. 1992;18(4):353-72 [1470924.001]
  • [Cites] Cancer Res. 1993 Aug 1;53(15):3632-7 [8101764.001]
  • [Cites] J Exp Med. 1994 Jul 1;180(1):53-66 [7516417.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2051-6 [7697593.001]
  • [Cites] Cancer Res. 1995 May 1;55(9):1817-9 [7728744.001]
  • [Cites] Thromb Haemost. 1995 Jan;73(1):59-65 [7740497.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8205-9 [7667269.001]
  • [Cites] Thromb Haemost. 1995 Jul;74(1):282-90 [8578473.001]
  • [Cites] Am J Physiol. 1997 Nov;273(5 Pt 2):H2091-104 [9374741.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9325-30 [9689079.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1999 Sep;19(9):2251-62 [10479670.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2130-5 [15699479.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2123-9 [15699480.001]
  • [Cites] Int J Oncol. 2005 Oct;27(4):1159-67 [16142335.001]
  • [Cites] Future Oncol. 2005 Jun;1(3):395-403 [16556013.001]
  • [Cites] Cancer Metastasis Rev. 1992 Nov;11(3-4):237-48 [1423816.001]
  • [Cites] FASEB J. 1992 Apr;6(7):2397-404 [1563592.001]
  • [Cites] Am J Clin Pathol. 1979 Jan;71(1):10-6 [420161.001]
  • [Cites] Oncol Rep. 2004 Oct;12(4):683-8 [15375485.001]
  • [Cites] Thromb Haemost. 2004 Sep;92(3):627-33 [15351861.001]
  • [Cites] J Thromb Haemost. 2004 Aug;2(8):1266-71 [15304029.001]
  • [Cites] Chest. 2004 Aug;126(2):601-7 [15302749.001]
  • [Cites] J Thromb Haemost. 2006 May;4(5):1056-62 [16689759.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1944-8 [15143088.001]
  • [Cites] Nat Med. 2004 May;10(5):502-9 [15098027.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2743-50 [15087389.001]
  • [Cites] Thromb Haemost. 2003 Sep;90(3):549-54 [12958625.001]
  • [Cites] J Thromb Haemost. 2003 Sep;1(9):1972-6 [12941039.001]
  • [Cites] Carbohydr Res. 2002 Nov 19;337(21-23):2239-43 [12433488.001]
  • [Cites] Thromb Haemost. 2002 Oct;88(4):686 [12362244.001]
  • [Cites] Thromb Haemost. 2002 Jun;87(6):930-6 [12083498.001]
  • [Cites] Semin Thromb Hemost. 2002 Feb;28(1):29-38 [11885023.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3302-9 [11071621.001]
  • (PMID = 17139378.001).
  • [ISSN] 0340-6245
  • [Journal-full-title] Thrombosis and haemostasis
  • [ISO-abbreviation] Thromb. Haemost.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL052622-09; United States / NHLBI NIH HHS / HL / R01 HL052622; United States / NHLBI NIH HHS / HL / R01 HL062244; United States / NHLBI NIH HHS / HL / HL062244-07; United States / NHLBI NIH HHS / HL / HL052622-09; United States / NIGMS NIH HHS / GM / GM038060-19; United States / NIGMS NIH HHS / GM / R01 GM038060; United States / NIGMS NIH HHS / GM / R01 GM038060-19; United States / NHLBI NIH HHS / HL / R01 HL062244-07
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Antineoplastic Agents; 0 / Enoxaparin; 0 / Factor Xa Inhibitors; 0 / Heparin, Low-Molecular-Weight; 0 / Lipoproteins; 0 / NA-LMWH; 0 / lipoprotein-associated coagulation inhibitor; 9001-26-7 / Prothrombin; 9002-04-4 / Factor IIa
  • [Other-IDs] NLM/ NIHMS75576; NLM/ PMC4114246
  •  go-up   go-down


26. Nakamura S, Chen G, Nakashima S, Matsuda H, Pei Y, Yoshikawa M: Brazilian natural medicines. IV. New noroleanane-type triterpene and ecdysterone-type sterol glycosides and melanogenesis inhibitors from the roots of Pfaffia glomerata. Chem Pharm Bull (Tokyo); 2010 May;58(5):690-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The ethyl acetate and 1-butanol soluble fractions of the roots of Pfaffia glomerata were found to show inhibitory effects on melanogenesis in theophylline-stimulated B16 melanoma 4A5 cells.
  • [MeSH-major] Amaranthaceae / chemistry. Antineoplastic Agents. Ecdysterone / chemistry. Glycosides / chemistry. Melanoma, Experimental. Oleanolic Acid / chemistry. Plant Roots / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20460798.001).
  • [ISSN] 1347-5223
  • [Journal-full-title] Chemical & pharmaceutical bulletin
  • [ISO-abbreviation] Chem. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glycosides; 0 / Plant Extracts; 0 / Sterols; 5289-74-7 / Ecdysterone; 6SMK8R7TGJ / Oleanolic Acid
  •  go-up   go-down


27. Itoh K, Hirata N, Masuda M, Naruto S, Murata K, Wakabayashi K, Matsuda H: Inhibitory effects of Citrus hassaku extract and its flavanone glycosides on melanogenesis. Biol Pharm Bull; 2009 Mar;32(3):410-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The CH-ext showed inhibition of melanogenesis without any effects on cell proliferation in cultured murine B16 melanoma cells after glucosamine exposure.

  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19252287.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Flavanones; 0 / Free Radical Scavengers; 0 / Glycosides; 0 / Melanins; 0 / Plant Extracts; 0 / Solvents; 3K9958V90M / Ethanol; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


28. Fëdorov ES, Manikhas GM, Petrishchëv NN, Dubina MV: [The role of gap junction communication in metastatic B16 melanoma in C57BL mice]. Vopr Onkol; 2006;52(4):433-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of gap junction communication in metastatic B16 melanoma in C57BL mice].
  • The study is concerned with the effects of non-specific blocking gap junction communication with oleamide as well as genesis and spreading of melanoma B16 metastases to the lung in mice C57B1.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinogens. Cell Communication. Gap Junctions. Melanoma, Experimental / ultrastructure. Oleic Acids / pharmacology

  • Hazardous Substances Data Bank. (Z)-9-OCTADECENAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17024817.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carcinogens; 0 / Oleic Acids; 7L25QK8BWO / oleylamide
  •  go-up   go-down


29. LeBlanc R, Dickson J, Brown T, Stewart M, Pati HN, VanDerveer D, Arman H, Harris J, Pennington W, Holt HL Jr, Lee M: Synthesis and cytotoxicity of epoxide and pyrazole analogs of the combretastatins. Bioorg Med Chem; 2005 Nov 1;13(21):6025-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The relatively coplanar conformation of a 3',3'',4',4'',5',5''-hexamethoxypyrazole 17 was in good agreement with the shape for 3',3'',4',4'',5'-pentamethoxypyrazole 16, which was determined from molecular mechanics optimization.
  • In vitro cytotoxicity of each class of compounds was obtained using a 72 h continuous exposure MTT assay against two murine cancer cell lines; B16 melanoma and L1210 leukemia.
  • In the majority of cases, the pyrazoles are generally more active than the epoxides, with the most active, 5-(3''-amino-4''-methoxyphenyl)-3-(3',4',5'-trimethoxyphenyl)pyrazole 21, possessing an IC(50) value of 5 and 2.4 microM (B16 and L1210, respectively).

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16055334.001).
  • [ISSN] 0968-0896
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / RR 16461-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bibenzyls; 0 / Epoxy Compounds; 0 / Pyrazoles; 0 / Stilbenes; 3QD5KJZ7ZJ / pyrazole; 82855-09-2 / combretastatin
  •  go-up   go-down


30. Simmons AD, Li B, Gonzalez-Edick M, Lin C, Moskalenko M, Du T, Creson J, VanRoey MJ, Jooss K: GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action. Cancer Immunol Immunother; 2007 Oct;56(10):1653-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To further define the mechanism of GM-CSF-secreting cancer immunotherapies, immunohistochemistry studies were performed using the B16F10 melanoma tumor model.
  • To evaluate the scope of the immune response generated by GM-CSF-secreting cancer immunotherapies, several related B16 melanoma tumor cell subclones that exist as a result of genetic drift in the original cell line were used to challenge mice previously immunized with GM-CSF-secreting B16F10 cells.
  • [MeSH-minor] Animals. Apoptosis. Cell Line, Tumor. Dendritic Cells / immunology. Disease Models, Animal. Female. Melanoma, Experimental. Mice. Mice, Inbred C57BL. Recombinant Proteins. T-Lymphocytes / immunology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17410360.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Recombinant Proteins; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


31. Schumacher LY, Vo DD, Garban HJ, Comin-Anduix B, Owens SK, Dissette VB, Glaspy JA, McBride WH, Bonavida B, Economou JS, Ribas A: Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). J Immunol; 2006 Apr 15;176(8):4757-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We established a murine model to test whether the proteasome inhibitor bortezomib could sensitize established B16 melanoma tumors to dendritic cell (DC)-activated immune effector cells.
  • B16 tumors had significantly decreased tumor outgrowth when treated with a combination of bortezomib and DC, regardless of whether the DC were loaded or not with a tumor Ag.
  • NF-kappaB nuclear transcription factor assay and gene-expression profiling of B16 treated with bortezomib was consistent with inhibition of NF-kappaB target genes leading to a proapoptotic phenotype.
  • In vitro lytic assays demonstrated that TNF-alpha, but not perforin, Fas-ligand, or TRAIL, was responsible for bortezomib-sensitized B16 cytotoxicity.
  • [MeSH-major] Boronic Acids / pharmacology. Dendritic Cells / immunology. Melanoma, Experimental / immunology. Melanoma, Experimental / therapy. Protease Inhibitors / pharmacology. Pyrazines / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16585569.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI-28697; United States / NCI NIH HHS / CA / CA-16042; United States / NCI NIH HHS / CA / K12 CA76905; United States / NCI NIH HHS / CA / K23 CA93376; United States / NCI NIH HHS / CA / P50 CA086306; United States / NCI NIH HHS / CA / R01 CA77623; United States / NCI NIH HHS / CA / R01 CA79976; United States / NCI NIH HHS / CA / T32 CA75956
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 0 / Tumor Necrosis Factor-alpha; 69G8BD63PP / Bortezomib
  •  go-up   go-down


32. Maksimovic-Ivanic D, Mijatovic S, Miljkovic D, Harhaji-Trajkovic L, Timotijevic G, Mojic M, Dabideen D, Cheng KF, McCubrey JA, Mangano K, Al-Abed Y, Libra M, Garotta G, Stosic-Grujicic S, Nicoletti F: The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt. Mol Cancer Ther; 2009 May;8(5):1169-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast to Saq, Saq-NO had no effect on the viability of primary cells and drastically reduced B16 melanoma growth in syngeneic C57BL/6 mice.
  • Saq-NO blocked the proliferation of C6 and B16 cells, up-regulated p53 expression, and promoted the differentiation of these two cell types into oligodendrocytes or Schwann-like cells, respectively.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. SAQUINAVIR .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19417156.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytostatic Agents; 31C4KY9ESH / Nitric Oxide; EC 2.7.11.1 / Oncogene Protein v-akt; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; L3JE09KZ2F / Saquinavir
  •  go-up   go-down


33. Kashiwagi H, McDunn JE, Goedegebuure PS, Gaffney MC, Chang K, Trinkaus K, Piwnica-Worms D, Hotchkiss RS, Hawkins WG: TAT-Bim induces extensive apoptosis in cancer cells. Ann Surg Oncol; 2007 May;14(5):1763-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined whether this construct (TAT-Bim) induced apoptosis in several cancer cell lines (T-cell lymphoma (EL4), pancreatic cancer (Panc-02), and melanoma (B16)) and whether TAT-Bim treatment synergized with radiation.
  • TAT-Bim significantly slowed tumor growth in murine models of pancreatic cancer and melanoma.
  • [MeSH-major] Apoptosis. Apoptosis Regulatory Proteins / pharmacology. Gene Products, tat / metabolism. Lymphoma, T-Cell / therapy. Melanoma / therapy. Membrane Proteins / pharmacology. Pancreatic Neoplasms / therapy. Proto-Oncogene Proteins / pharmacology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17206479.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA082841; United States / NIGMS NIH HHS / GM / GM044118; United States / NIGMS NIH HHS / GM / GM055194; United States / NCI NIH HHS / CA / P50 CA94056
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Bcl-2-like protein 11; 0 / Gene Products, tat; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins
  •  go-up   go-down


34. Rice JR, Gerberich JL, Nowotnik DP, Howell SB: Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin Cancer Res; 2006 Apr 1;12(7 Pt 1):2248-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: Antitumor activity was assessed in mice bearing B16F10 melanoma and M5076 and 2008 ovarian carcinomas.
  • When given at their respective maximum tolerated doses, the antitumor activity of AP5346 was superior to that of oxaliplatin against both the B16 melanoma and 2008 human ovarian carcinoma.
  • AP5346 delivered 16.3-fold more Pt to the tumor and 14.2-fold more Pt to tumor DNA than oxaliplatin based on AUC((1-168)).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / pharmacokinetics. Drug Delivery Systems. Melanoma / drug therapy. Organoplatinum Compounds / pharmacokinetics. Ovarian Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • SciCrunch. DrugBank: Data: Chemical .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16609041.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 0 / ProLindac; 9007-49-2 / DNA
  •  go-up   go-down


35. Buhtoiarov IN, Lum H, Berke G, Paulnock DM, Sondel PM, Rakhmilevich AL: CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. J Immunol; 2005 May 15;174(10):6013-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraperitoneal injection of anti-CD40 mAb into C57BL/6 mice resulted in activation of peritoneal macrophages capable of suppressing B16 melanoma cell proliferation in vitro, an effect that was greatly enhanced by LPS and observed against several murine and human tumor cell lines.
  • [MeSH-major] Antigens, CD40 / immunology. Antigens, CD40 / metabolism. Interferon-gamma / physiology. Macrophage Activation / immunology. Macrophages, Peritoneal / immunology. Macrophages, Peritoneal / metabolism. Melanoma, Experimental / immunology. Melanoma, Experimental / prevention & control

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15879094.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA087025; United States / NIGMS NIH HHS / GM / T32 GM008692; United States / NCI NIH HHS / CA / CA87025
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD40; 0 / Ligands; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


36. Bruhn KW, Craft N, Nguyen BD, Yip J, Miller JF: Characterization of anti-self CD8 T-cell responses stimulated by recombinant Listeria monocytogenes expressing the melanoma antigen TRP-2. Vaccine; 2005 Jul 21;23(33):4263-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of anti-self CD8 T-cell responses stimulated by recombinant Listeria monocytogenes expressing the melanoma antigen TRP-2.
  • We constructed a recombinant strain of Listeria monocytogenes (rLM) expressing murine tyrosinase-related protein-2 (TRP-2), a nonmutated melanocyte-derived differentiation antigen highly expressed in melanomas.
  • Peptide-loaded target cells were lysed in vitro by TRP-2-specific T cells in cytotoxicity assays, and mice immunized and boosted with rLM expressing TRP-2 were functionally protected from subcutaneous challenge with B16 melanoma cells.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913853.001).
  • [ISSN] 0264-410X
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA127565; United States / NIGMS NIH HHS / GM / GM07104; United States / NCI NIH HHS / CA / R01 CA84008-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Recombinant Fusion Proteins; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.3.12 / dopachrome isomerase
  •  go-up   go-down


37. Li D, Wang H, Xiang JJ, Deng N, Wang PP, Kang YL, Tao J, Xu M: Monoclonal antibodies targeting basic fibroblast growth factor inhibit the growth of B16 melanoma in vivo and in vitro. Oncol Rep; 2010 Aug;24(2):457-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal antibodies targeting basic fibroblast growth factor inhibit the growth of B16 melanoma in vivo and in vitro.
  • Up-regulated basic fibroblast growth factor (bFGF or FGF-2) plays an important role in the development and metastasis of melanoma; therefore, neutralizing antibodies to bFGF may suppress melanoma growth.
  • Anti-bFGF mAbs significantly inhibit the proliferation and induce apoptosis of B16 cells, and show inhibitory effects on the migration of B16F10 cells and the tube formation of human umbilical vein endothelial cells (HUVECs) in vitro.
  • Treatment of B16 melanoma spheroids with anti-bFGF mAbs in vivo results in significant reduction in tumor size and prolonged survival time of animals.
  • Our data indicate that anti-bFGF mAbs are potential therapeutic candidates for melanoma therapy by effectively suppressing the melanoma growth through inhibition of angiogenesis and induction of apoptosis in the tumor.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Cell Proliferation / drug effects. Fibroblast Growth Factor 2 / antagonists & inhibitors. Melanoma, Experimental / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20596633.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


38. Mastrofrancesco A, Kokot A, Eberle A, Gibbons NC, Schallreuter KU, Strozyk E, Picardo M, Zouboulis CC, Luger TA, Böhm M: KdPT, a tripeptide derivative of alpha-melanocyte-stimulating hormone, suppresses IL-1 beta-mediated cytokine expression and signaling in human sebocytes. J Immunol; 2010 Aug 1;185(3):1903-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Importantly, KdPT did not bind to MC-1Rs, as demonstrated by blocking experiments with a peptide analog of Agouti signaling protein and by binding assays using MC-1R-expressing B16 melanoma cells.
  • [MeSH-minor] Animals. Cell Line. Cell Line, Transformed. DNA-Binding Proteins / physiology. Humans. I-kappa B Kinase / antagonists & inhibitors. I-kappa B Kinase / metabolism. I-kappa B Proteins / antagonists & inhibitors. I-kappa B Proteins / metabolism. Interleukin-6 / antagonists & inhibitors. Interleukin-8 / antagonists & inhibitors. Melanoma, Experimental. Mice

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20610647.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / DNA-Binding Proteins; 0 / I-kappa B Proteins; 0 / Immunosuppressive Agents; 0 / Interleukin-1beta; 0 / Interleukin-6; 0 / Interleukin-8; 0 / Peptide Fragments; 117027-34-6 / interleukin 1beta (193-195); 139874-52-5 / NF-kappaB inhibitor alpha; 581-05-5 / alpha-MSH; EC 2.7.11.10 / I-kappa B Kinase
  •  go-up   go-down


39. Abduvaliev AA, Gil'dieva MS: [Differential trypan blue staining of tumor cells for the determination of apoptosis]. Klin Lab Diagn; 2006 Feb;(2):36-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The paper also gives data of the comparative studies of the content of apoptotic cells in experimental melanoma B-16 though differential trypan blue staining and classical morphostructural analysis.
  • [MeSH-major] Apoptosis. Breast Neoplasms / pathology. Coloring Agents. Immunohistochemistry. Melanoma / pathology. Trypan Blue

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. Trypan blue .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16610632.001).
  • [ISSN] 0869-2084
  • [Journal-full-title] Klinicheskaia laboratornaia diagnostika
  • [ISO-abbreviation] Klin. Lab. Diagn.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Coloring Agents; I2ZWO3LS3M / Trypan Blue
  •  go-up   go-down


40. Prakash J, Beljaars L, Harapanahalli AK, Zeinstra-Smith M, de Jager-Krikken A, Hessing M, Steen H, Poelstra K: Tumor-targeted intracellular delivery of anticancer drugs through the mannose-6-phosphate/insulin-like growth factor II receptor. Int J Cancer; 2010 Apr 15;126(8):1966-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • M6P-HSA specifically bound and internalized into M6P/IGF-IIR-expressing B16 melanoma cells as demonstrated with radioactive studies and anti-HSA immunostaining.
  • In B16 tumor-bearing mice, Dox-HSA-M6P significantly inhibited the tumor growth whereas an equimolar dose of free doxorubicin did not show any anti-tumor effect.

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19795464.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Carriers; 0 / Mannosephosphates; 0 / Receptor, IGF Type 2; 0 / Serum Albumin; 3672-15-9 / mannose-6-phosphate; 80168379AG / Doxorubicin
  •  go-up   go-down


41. Genady AR: Promising carboranylquinazolines for boron neutron capture therapy: synthesis, characterization, and in vitro toxicity evaluation. Eur J Med Chem; 2009 Jan;44(1):409-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vitro toxicity was performed with B16 melanoma cells and showed that the connection of hydrophilic nido-carborane to quinazoline moiety decreases the compound's toxicity.
  • [MeSH-minor] Cell Line, Tumor. Humans. Melanoma, Experimental / drug therapy. Spectrum Analysis. Structure-Activity Relationship

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18407378.001).
  • [ISSN] 1768-3254
  • [Journal-full-title] European journal of medicinal chemistry
  • [ISO-abbreviation] Eur J Med Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boranes; 0 / Quinazolines
  •  go-up   go-down


42. Funaba M, Murakami M, Ikeda T, Ogawa K, Tsuchida K, Sugino H: Identification of tocopherol-associated protein as an activin/TGF-beta-inducible gene in mast cells. Biochim Biophys Acta; 2006 Aug;1763(8):900-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Activin A-induced Tap expression was detected in BMMC but not in RAW264 macrophage-like cells, B16 melanoma cells or P19 embryonic carcinoma cells.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16872693.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide; 0 / Benzamides; 0 / Carrier Proteins; 0 / DNA, Complementary; 0 / Dioxoles; 0 / Lipoproteins; 0 / Receptors, Transforming Growth Factor beta; 0 / Smad3 Protein; 0 / Smad3 protein, mouse; 0 / Tgfb1 protein, mouse; 0 / Trans-Activators; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; 0 / activin A; 0 / tocopherol-associated protein, mouse; 104625-48-1 / Activins; 93443-12-0 / Inhibin-beta Subunits; EC 2.7.11.30 / Activin Receptors, Type I
  •  go-up   go-down


43. Ty N, Dupeyre G, Chabot GG, Seguin J, Quentin L, Chiaroni A, Tillequin F, Scherman D, Michel S, Cachet X: Structure-activity relationships of indole compounds derived from combretastatin A4: synthesis and biological screening of 5-phenylpyrrolo[3,4-a]carbazole-1,3-diones as potential antivascular agents. Eur J Med Chem; 2010 Sep;45(9):3726-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intermediate tetrahydro[3,4-a]carbazoles and their corresponding carbazoles were submitted to biological screening tests involved in antivascular action, including the cytotoxicity against murine B16 melanoma cells, the rounding up of endothelial cells (EA.hy 926) and the inhibition of tubulin polymerization.

  • Hazardous Substances Data Bank. CARBAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20538383.001).
  • [ISSN] 1768-3254
  • [Journal-full-title] European journal of medicinal chemistry
  • [ISO-abbreviation] Eur J Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carbazoles; 0 / Stilbenes; 0 / Tubulin; 0P2197HHHN / carbazole; I5590ES2QZ / fosbretabulin
  •  go-up   go-down


44. Trabado S, Nguyen Van Binh P, Martin C, Lafarge-Frayssinet C, Thevenin M, Baudouin F, Warnet JM, Duc HT: Modulated expression of cell surface molecules and in vivo outgrowth of modified melanoma cells. Biomed Pharmacother; 2006 Dec;60(10):693-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulated expression of cell surface molecules and in vivo outgrowth of modified melanoma cells.
  • Modulation of cell surface molecules involved in immune recognition and cellular interactions (class I major histocompatibility complex or MHC-I, B7.1 or CD80, integrin alpha4 or CD49d, tetraspanins CD9, CD81) was examined in modified B16 melanoma cells displaying either inhibited IGF-I expression or transfected OVA encoding gene.
  • However downregulation of tetraspanin CD9 was observed in modified IGF-I but not in OVA encoding gene inserted melanoma cells.
  • Inoculated into syngeneic recipients, the modified melanoma cells exhibited significant delayed outgrowth with a reduction in the percentage of lethal tumors observed essentially in hosts injected with inhibited IGF-I expression cells.
  • [MeSH-major] Antigens, Surface / metabolism. Melanoma, Experimental / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17071049.001).
  • [ISSN] 0753-3322
  • [Journal-full-title] Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
  • [ISO-abbreviation] Biomed. Pharmacother.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antigens, CD; 0 / Antigens, CD80; 0 / Antigens, CD81; 0 / Antigens, CD9; 0 / Antigens, Surface; 0 / Cd81 protein, mouse; 0 / Cd9 protein, mouse; 0 / DNA, Antisense; 0 / Histocompatibility Antigens Class I; 0 / Membrane Glycoproteins; 143198-26-9 / Integrin alpha4; 3XQ2233B0B / Hygromycin B; 67763-96-6 / Insulin-Like Growth Factor I; 9006-59-1 / Ovalbumin
  •  go-up   go-down


45. Shibata S, Okano S, Yonemitsu Y, Onimaru M, Sata S, Nagata-Takeshita H, Inoue M, Zhu T, Hasegawa M, Moroi Y, Furue M, Sueishi K: Induction of efficient antitumor immunity using dendritic cells activated by recombinant Sendai virus and its modulation by exogenous IFN-beta gene. J Immunol; 2006 Sep 15;177(6):3564-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Even though the expression of surface markers for DC activation ex vivo did not always reach the level attained by an optimized amount of LPS, superior antitumor effects to B16F1 melanoma, namely tumor elimination and survival, were obtained with use of SeV-GFP/DC as compared with those seen with LPS/DC in vivo, and the effect was enhanced by SeV/DC-expressing IFN-beta (SeV-murine IFN-beta (mIFN-beta)/DC).
  • In case of the treatment of an established tumor of B16F10 (7-9 mm in diameter), a highly malignant subline of B16 melanoma, SeV-modified DCs (both SeV-GFP/DC and SeV-mIFN-beta/DC), but not immature DC and LPS/DC, dramatically improved the survival of animals.
  • [MeSH-major] Dendritic Cells / transplantation. Interferon-beta / genetics. Melanoma, Experimental / immunology. Melanoma, Experimental / prevention & control. Sendai virus / immunology

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16951315.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vaccines, Synthetic; 77238-31-4 / Interferon-beta
  •  go-up   go-down


46. Saji H, Song W, Furumoto K, Kato H, Engleman EG: Systemic antitumor effect of intratumoral injection of dendritic cells in combination with local photodynamic therapy. Clin Cancer Res; 2006 Apr 15;12(8):2568-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: BALB/c or C57Bl/6 mice were injected s.c. with CT26 colorectal carcinoma cells and B16 melanoma cells, respectively, and following 10 to 12 days of tumor growth, the tumors were treated with PDT alone or PDT followed by IT-DC or IT-PBS.
  • RESULTS: Whereas neither PDT nor IT-DC alone was effective, PDT + IT-DC eradicated both CT26 and B16 tumors in a significant proportion of animals and prolonged the survival of mice of which the tumors were not cured.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2006 Apr 15;12(8):2385-9 [16638842.001]
  • (PMID = 16638867.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL57443; United States / NCI NIH HHS / CA / K08CA105064
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


47. Klages K, Mayer CT, Lahl K, Loddenkemper C, Teng MW, Ngiow SF, Smyth MJ, Hamann A, Huehn J, Sparwasser T: Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res; 2010 Oct 15;70(20):7788-99
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.
  • We showed that Foxp3(+) Treg depletion induced partial regression of established ovalbumin (OVA)-expressing B16 melanoma, which was associated with an increased intratumoral accumulation of activated CD8(+) cytotoxic T cells.
  • [MeSH-major] Forkhead Transcription Factors / deficiency. Lymphocyte Depletion / methods. Melanoma / immunology. Melanoma, Experimental / immunology. T-Lymphocytes, Regulatory / immunology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • (PMID = 20924102.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantigens; 0 / Cancer Vaccines; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Foxp3 protein, mouse; 0 / Interleukin-2 Receptor alpha Subunit; 9006-59-1 / Ovalbumin
  •  go-up   go-down


48. Søndergaard H, Galsgaard ED, Bartholomaeussen M, Straten PT, Odum N, Skak K: Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes. J Immunother; 2010 Apr;33(3):236-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we have compared the efficacy of subcutaneous and intratumoral (IT) administration of IL-21 protein in two syngeneic mouse tumor models, RenCa renal cell carcinoma and B16 melanoma, and investigated the mechanisms by which IL-21 enhances CD8 T-cell-mediated antitumor immunity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20445344.001).
  • [ISSN] 1537-4513
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukins; 0 / interleukin-21; 82115-62-6 / Interferon-gamma; EC 3.4.21.- / Granzymes
  •  go-up   go-down


49. Inglefield JR, Dumitru CD, Alkan SS, Gibson SJ, Lipson KE, Tomai MA, Larson CJ, Vasilakos JP: TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN. J Interferon Cytokine Res; 2008 Apr;28(4):253-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vivo, six doses of 852A administration significantly delayed the onset of lung colonies in a B16 melanoma model.
  • [MeSH-minor] Aminoquinolines / pharmacology. Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Culture Media, Conditioned / pharmacology. Humans. Leukocytes, Mononuclear / drug effects. Lung / drug effects. Lung / pathology. Melanoma / pathology. Mice. Oligodeoxyribonucleotides / pharmacology. Subcellular Fractions / drug effects

  • Hazardous Substances Data Bank. Imiquimod .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18439103.001).
  • [ISSN] 1079-9907
  • [Journal-full-title] Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
  • [ISO-abbreviation] J. Interferon Cytokine Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / CpG ODN 2216; 0 / Culture Media, Conditioned; 0 / Interferon Type I; 0 / N-(4-(4-amino-2-ethyl-1H-imidazo(4,5c)quinolin-1-yl)butyl)methanesulfonamide; 0 / Oligodeoxyribonucleotides; 0 / Quinolines; 0 / Sulfonamides; 0 / TLR7 protein, human; 0 / Toll-Like Receptor 7; 99011-02-6 / imiquimod
  •  go-up   go-down


50. Chopra A, Kim TS, O-Sullivan I, Martinez D, Cohen EP: Combined therapy of an established, highly aggressive breast cancer in mice with paclitaxel and a unique DNA-based cell vaccine. Int J Cancer; 2006 Jun 1;118(11):2888-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The immunity was specific, as immunization with a vaccine prepared by transfer of DNA from B16 melanoma cells into the fibroblasts failed to induce immunity to the breast cancer.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16380982.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / NIDCR NIH HHS / DE / 1 R01 DE013970-O1A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Cancer Vaccines; 0 / Vaccines, DNA; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


56. Shi G, Mao J, Yu G, Zhang J, Wu J: Tumor vaccine based on cell surface expression of DcR3/TR6. J Immunol; 2005 Apr 15;174(8):4727-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cell surface TR6-based tumor vaccine was also effective against low antigenicity tumors, such as B16 melanoma; co-administration of bacillus Calmette-Guérin further enhanced the vaccine's efficacy.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15814697.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / Immunologic Factors; 0 / Membrane Glycoproteins; 0 / Receptors, Cell Surface; 0 / Receptors, Tumor Necrosis Factor; 0 / Receptors, Tumor Necrosis Factor, Member 6b; 0 / TNFRSF6B protein, human
  •  go-up   go-down


57. Marincek BC, Kühnle MC, Srokowski C, Schild H, Hämmerling G, Momburg F: Heat shock protein-antigen fusions lose their enhanced immunostimulatory capacity after endotoxin depletion. Mol Immunol; 2008 Nov;46(1):181-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Importantly, prophylactic and therapeutic treatment with endotoxin-depleted HSP70-OVA together with CpG significantly delayed the outgrowth of OVA-expressing B16 melanoma cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18804283.001).
  • [ISSN] 0161-5890
  • [Journal-full-title] Molecular immunology
  • [ISO-abbreviation] Mol. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antigens; 0 / CPG-oligonucleotide; 0 / Endotoxins; 0 / HSP70 Heat-Shock Proteins; 0 / Oligodeoxyribonucleotides; 0 / Receptors, Antigen, T-Cell; 0 / Recombinant Fusion Proteins; 9006-59-1 / Ovalbumin
  •  go-up   go-down


58. Matsushita N, Pilon-Thomas SA, Martin LM, Riker AI: Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods; 2008 Apr 20;333(1-2):167-79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative methodologies of regulatory T cell depletion in a murine melanoma model.
  • There has been recent interest in the depletion of regulatory T cells (Tregs) as part of a multi-faceted approach to the immunotherapy of melanoma patients.
  • Utilization of DD resulted in a >50% Treg cell reduction without parallel cytocidal effects upon other T cell subsets but did not enhance anti-tumor immunity against B16 melanoma.
  • We therefore conclude that PC61 administration was the most effective method of reducing Tregs in a murine melanoma model in addition to providing evidence of a synergistic effect when combined with DC-based immunotherapy.

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Oct 15;108(8):2655-61 [16763205.001]
  • [Cites] Transplantation. 2006 Jun 15;81(11):1549-57 [16770244.001]
  • [Cites] J Exp Med. 2000 Jul 17;192(2):295-302 [10899916.001]
  • [Cites] J Exp Med. 2000 Jul 17;192(2):303-10 [10899917.001]
  • [Cites] Nat Genet. 2001 Jan;27(1):18-20 [11137992.001]
  • [Cites] Nat Genet. 2001 Jan;27(1):20-1 [11137993.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):376-88 [11208829.001]
  • [Cites] J Exp Med. 2001 Sep 17;194(6):823-32 [11560997.001]
  • [Cites] Cancer Res. 2001 Dec 1;61(23):8513-9 [11731436.001]
  • [Cites] Nat Immunol. 2002 Feb;3(2):135-42 [11812990.001]
  • [Cites] Immunity. 2002 Feb;16(2):311-23 [11869690.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2983-8 [11854473.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1021-32 [11948109.001]
  • [Cites] J Immunother. 2002 May-Jun;25(3):207-17 [12000862.001]
  • [Cites] J Immunother. 2002 May-Jun;25(3):243-51 [12000866.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):606-12 [12576425.001]
  • [Cites] Nat Immunol. 2003 Apr;4(4):330-6 [12612578.001]
  • [Cites] Nat Immunol. 2003 Apr;4(4):337-42 [12612581.001]
  • [Cites] Curr Opin Mol Ther. 2003 Feb;5(1):44-51 [12669470.001]
  • [Cites] Jpn J Cancer Res. 2002 Aug;93(8):911-6 [12716469.001]
  • [Cites] J Exp Med. 2003 Jul 21;198(2):259-66 [12874259.001]
  • [Cites] J Immunother. 2003 Sep-Oct;26(5):385-93 [12973027.001]
  • [Cites] Eur J Immunol. 2004 Feb;34(2):336-44 [14768038.001]
  • [Cites] Annu Rev Immunol. 2004;22:531-62 [15032588.001]
  • [Cites] J Immunol. 2004 May 15;172(10):5823-7 [15128759.001]
  • [Cites] J Immunol. 2004 Jul 15;173(2):1444-53 [15240741.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] J Exp Med. 2004 Sep 20;200(6):771-82 [15381730.001]
  • [Cites] Cancer Res. 1975 Jan;35(1):218-24 [1109790.001]
  • [Cites] Contemp Top Immunobiol. 1984;13:243-57 [6610533.001]
  • [Cites] Adv Immunol. 1984;35:89-155 [6235727.001]
  • [Cites] J Exp Med. 1986 Oct 1;164(4):1179-92 [2944983.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Jun;85(11):3980-4 [3131768.001]
  • [Cites] Cancer Res. 1989 Apr 1;49(7):1649-54 [2522344.001]
  • [Cites] Annu Rev Immunol. 1991;9:271-96 [1910679.001]
  • [Cites] Nat Med. 1995 Jul;1(7):649-53 [7585145.001]
  • [Cites] Nat Med. 1995 Dec;1(12):1297-302 [7489412.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3245-87 [9345009.001]
  • [Cites] J Exp Med. 1998 Jul 20;188(2):287-96 [9670041.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9482-7 [9689106.001]
  • [Cites] Protein Eng. 1998 Sep;11(9):811-7 [9796831.001]
  • [Cites] Int Immunol. 1998 Dec;10(12):1969-80 [9885918.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3128-33 [10397255.001]
  • [Cites] J Immunol. 2005 Jan 1;174(1):90-8 [15611231.001]
  • [Cites] Am J Transplant. 2005 Mar;5(3):454-64 [15707399.001]
  • [Cites] J Immunother. 2005 Mar-Apr;28(2):120-8 [15725955.001]
  • [Cites] J Immunol. 2005 Mar 15;174(6):3344-51 [15749866.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2862-8 [15591121.001]
  • [Cites] Nat Immunol. 2005 Apr;6(4):345-52 [15785760.001]
  • [Cites] J Immunother. 2005 Nov-Dec;28(6):582-92 [16224276.001]
  • [Cites] J Clin Invest. 2005 Dec;115(12):3623-33 [16308572.001]
  • [Cites] J Clin Oncol. 2005 Dec 10;23(35):8968-77 [16204013.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5941-6 [16585503.001]
  • [Cites] J Immunol. 1999 Nov 15;163(10):5211-8 [10553041.001]
  • (PMID = 18295790.001).
  • [ISSN] 0022-1759
  • [Journal-full-title] Journal of immunological methods
  • [ISO-abbreviation] J. Immunol. Methods
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA087989-02; United States / NCI NIH HHS / CA / K12 CA087989; United States / NCI NIH HHS / CA / K12 CA 87989; United States / NCI NIH HHS / CA / K12 CA087989-02
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Receptors, Interleukin-2; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox; 8N3DW7272P / Cyclophosphamide
  • [Other-IDs] NLM/ NIHMS45951; NLM/ PMC2577585
  •  go-up   go-down


59. Fu Z, Lu R, Jia J, Zhao L, Ma R, Lv JQ, Li XL, Chen LJ, Zhang HL, Wang L, Yao Z: Inhibition of five xenografted human cancers and two murine cancers by the tripeptide tyroservatide. Anticancer Drugs; 2007 Apr;18(4):467-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study aimed to observe the effects of tyroservatide on other five human carcinomas: A549 (nonsmall cell lung carcinoma), BGC-823 (gastric cancer), MCF-7 (breast cancer), K562 (leukemia), A375 (melanoma) and two murine cancers: Lewis lung cancer and B16 (melanoma) in vivo.
  • Tyroservatide could significantly inhibit the growth of human lung carcinoma A549, human leukemia K562 and human melanoma A375 in nude mice (P<0.05).
  • In addition, tyroservatide significantly inhibited the subcutaneous tumor growth of Lewis lung carcinoma and B16 melanoma (P<0.05).

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17351399.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indicators and Reagents; 0 / Oligopeptides; 0 / tripeptide tyroservatide
  •  go-up   go-down


60. Saito H, Mitobe K, Ito A, Sugawara Y, Maruyama K, Minamiya Y, Motoyama S, Yoshimura N, Ogawa J: Self-regulating hyperthermia induced using thermosensitive ferromagnetic material with a low Curie temperature. Cancer Sci; 2008 Apr;99(4):805-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hyperthermia has been used for many years to treat a variety of malignant tumors.
  • B16 melanoma cells were subcutaneously injected into the backs of C57BL/6 mice, after which tumors were allowed to grow to 5 mm in diameter.
  • Our findings suggest that repeated treatment with magnetically-induced self-regulating hyperthermia, mediated by FMPs with a low Tc, is an effective means of suppressing melanoma growth.
  • [MeSH-major] Ferric Compounds / therapeutic use. Hyperthermia, Induced / methods. Magnetics / therapeutic use. Melanoma, Experimental / therapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18294293.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ferric Compounds; 1317-54-0 / ferrite
  •  go-up   go-down


61. Singhal SS, Singhal J, Yadav S, Dwivedi S, Boor PJ, Awasthi YC, Awasthi S: Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (Ral-binding protein 1). Cancer Res; 2007 May 01;67(9):4382-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is frequently overexpressed in malignant cells and plays a prominent antiapoptotic role selectively in cancer cells through its ability to control cellular concentration of proapoptotic oxidized lipid byproducts.
  • In the absence of chemotherapy, depletion or inhibition of RALBP1 causes regression of syngeneic mouse B16 melanoma.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483352.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 104661; United States / NCI NIH HHS / CA / CA 77495; United States / NIEHS NIH HHS / ES / ES 012171
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ATP-Binding Cassette Transporters; 0 / DNA, Antisense; 0 / GTPase-Activating Proteins; 0 / Immunoglobulin G; 0 / RALBP1 protein, human; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


62. Carrière V, Colisson R, Jiguet-Jiglaire C, Bellard E, Bouche G, Al Saati T, Amalric F, Girard JP, M'Rini C: Cancer cells regulate lymphocyte recruitment and leukocyte-endothelium interactions in the tumor-draining lymph node. Cancer Res; 2005 Dec 15;65(24):11639-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report here that, in C57BL/6 mice, the recruitment of naïve lymphocytes is impaired in LNs draining a B16 melanoma tumor.
  • [MeSH-major] Endothelium, Lymphatic / cytology. Endothelium, Lymphatic / immunology. Leukocytes / metabolism. Lymph Nodes / immunology. Lymphocytes / physiology. Melanoma, Experimental / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357175.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ccl21c protein, mouse; 0 / Chemokine CCL21; 0 / Chemokines, CC; 0 / Membrane Glycoproteins; 0 / P-Selectin; 0 / P-selectin ligand protein; 126880-86-2 / L-Selectin
  •  go-up   go-down


63. Qin YS, Zhang X, Li L, Yu HL: [Effect of histamine on metastasis of melanoma B16 cell xenograft in C57BL/6 mice]. Ai Zheng; 2007 Aug;26(8):833-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of histamine on metastasis of melanoma B16 cell xenograft in C57BL/6 mice].
  • METHODS: Cultured melanoma B16 cells were inoculated into the left armpit of C57BL/6 mice to develop melanoma.
  • RESULTS: All the mice developed melanoma after inoculation.
  • CONCLUSION: Histamine can inhibit the metastasis of melanoma B16 cells in C57BL/6 mice either through lymphatic or hemal route, and this partly because of its inhibitory effect on tumor growth.
  • [MeSH-major] Histamine / pharmacology. Lung Neoplasms / secondary. Lymphatic Metastasis / pathology. Melanoma, Experimental / pathology. Splenic Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. HISTAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697542.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 820484N8I3 / Histamine
  •  go-up   go-down


64. Zhang H, Wang W, Li Q, Huang W: Fusion protein of ATPase domain of Hsc70 with TRP2 acting as a tumor vaccine against B16 melanoma. Immunol Lett; 2006 Jun 15;105(2):167-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fusion protein of ATPase domain of Hsc70 with TRP2 acting as a tumor vaccine against B16 melanoma.
  • [MeSH-major] Adenosine Triphosphatases / immunology. Cancer Vaccines / immunology. HSC70 Heat-Shock Proteins / chemistry. HSC70 Heat-Shock Proteins / immunology. Melanoma / immunology. Melanoma / prevention & control. Membrane Proteins / immunology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16580737.001).
  • [ISSN] 0165-2478
  • [Journal-full-title] Immunology letters
  • [ISO-abbreviation] Immunol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / HSC70 Heat-Shock Proteins; 0 / Membrane Proteins; 0 / Recombinant Fusion Proteins; 0 / Trp2 protein, vertebrate; EC 3.6.1.- / Adenosine Triphosphatases
  •  go-up   go-down


65. Sato K, Morita M, Ichikawa C, Takahashi H, Toriyama M: Depigmenting mechanisms of all-trans retinoic acid and retinol on B16 melanoma cells. Biosci Biotechnol Biochem; 2008 Oct;72(10):2589-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Depigmenting mechanisms of all-trans retinoic acid and retinol on B16 melanoma cells.
  • We assessed the effects of ATRA and retinol on melanogenesis in murine B16 melanoma cells.
  • In the present study, ATRA and retinol inhibited melanin synthesis in melanoma cells stimulated by alpha-melanocyte stimulating hormone (alpha-MSH) or 3-isobutyl-1-methylxanthine (IBMX).
  • [MeSH-major] Melanoma / metabolism. Pigmentation / drug effects. Tretinoin / pharmacology. Vitamin A / pharmacology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Vitamin A.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. VITAMIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18838813.001).
  • [ISSN] 1347-6947
  • [Journal-full-title] Bioscience, biotechnology, and biochemistry
  • [ISO-abbreviation] Biosci. Biotechnol. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Melanins; 11103-57-4 / Vitamin A; 5688UTC01R / Tretinoin; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


66. Yoshiura K, Nishishita T, Nakaoka T, Yamashita N, Yamashita N: Inhibition of B16 melanoma growth and metastasis in C57BL mice by vaccination with a syngeneic endothelial cell line. J Exp Clin Cancer Res; 2009;28:13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of B16 melanoma growth and metastasis in C57BL mice by vaccination with a syngeneic endothelial cell line.
  • Prior to ninth vaccination, the mice were challenged with B16/F10 melanoma cells by subcutaneous inoculation on the back for the tumor growth model or by tail venous injection for the lung metastasis model.
  • CONCLUSION: These results suggest that vaccination with an autologous endothelial cell line may be effective against melanoma.
  • [MeSH-major] Cancer Vaccines / immunology. Endothelial Cells / immunology. Immunotherapy, Adoptive / methods. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. Melanoma, Experimental / therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):2179-89 [15041739.001]
  • [Cites] Cancer Sci. 2004 Jan;95(1):85-90 [14720332.001]
  • [Cites] Cancer Cell. 2004 Nov;6(5):507-16 [15542434.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):553-61 [15695399.001]
  • [Cites] Nat Rev Cancer. 2005 Jun;5(6):436-46 [15928674.001]
  • [Cites] Oncology. 2005;69(1):81-7 [16088235.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8201-7 [16299253.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1813-9 [16551866.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9208-13 [16754857.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5834-40 [17020991.001]
  • [Cites] Eur J Cancer. 2008 Feb;44(3):383-90 [18060766.001]
  • [Cites] Science. 2000 Aug 18;289(5482):1197-202 [10947988.001]
  • [Cites] Nat Med. 2000 Oct;6(10):1160-6 [11017149.001]
  • [Cites] Vaccine. 2000 Dec 8;19(9-10):1294-303 [11137269.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11545-50 [11553767.001]
  • [Cites] Chin Med J (Engl). 1999 Feb;112(2):157-61 [11593585.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7846-54 [11691802.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4182-94 [11751519.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2034-42 [11929822.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2567-75 [11980651.001]
  • [Cites] Immunol Invest. 2002 Feb;31(1):51-69 [11990463.001]
  • [Cites] J Exp Med. 2002 Jun 17;195(12):1575-84 [12070285.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3906-27 [12228212.001]
  • [Cites] Nat Med. 2002 Dec;8(12):1369-75 [12415261.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):600-7 [12566302.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] J Biol Chem. 2003 Jun 13;278(24):21831-6 [12651849.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1815-23 [12750177.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • (PMID = 19183492.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Cancer Vaccines
  • [Other-IDs] NLM/ PMC2646687
  •  go-up   go-down


67. Hong J, Zhao Y, Huang W: Blocking c-myc and stat3 by E. coli expressed and enzyme digested siRNA in mouse melanoma. Biochem Biophys Res Commun; 2006 Sep 22;348(2):600-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blocking c-myc and stat3 by E. coli expressed and enzyme digested siRNA in mouse melanoma.
  • Our experimental data revealed that the mixed treatment of esiC-MYC and esiSTAT3 had a better inhibition effect than the single treatment of esiC-MYC or esiSTAT3 on mouse B16 melanoma.
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Line, Tumor. Cell Proliferation / drug effects. Escherichia coli / genetics. Escherichia coli / metabolism. Melanoma, Experimental / drug therapy. Mice

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890193.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Small Interfering; 0 / STAT3 Transcription Factor
  •  go-up   go-down


68. Park D, Lapteva N, Seethammagari M, Slawin KM, Spencer DM: An essential role for Akt1 in dendritic cell function and tumor immunotherapy. Nat Biotechnol; 2006 Dec;24(12):1581-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • M(F)-DeltaAkt-transduced DCs enhanced T-cell proliferation, activation and long-term memory responses, enabling eradication of large pre-established lymphomas and aggressive B16 melanomas.
  • [MeSH-minor] Animals. Biosynthetic Pathways. Carboxylic Ester Hydrolases / metabolism. Cell Differentiation. Humans. Immunotherapy / methods. Lymphoma / therapy. Melanoma / therapy. Mice. Mice, Knockout. Mitochondrial Proteins / metabolism. Skin Neoplasms / therapy


69. Chemin C, Péan JM, Le Pape A, Delbos JM, German-Fattal M, Wüthrich P, Couvreur P: Biodistribution and anticancer activity of a new Vinca alkaloid encapsulated into long-circulating liposomes. J Liposome Res; 2010 Mar;20(1):62-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liposome accumulation was much more important in the case of B16 melanoma, compared to H460 tumor, with both inoculated subcutaneously and with comparable size.
  • The liposomal formulation injected into mice bearing B16 melanoma allowed a 10-fold accumulation of S12363 into the tumor interstitium, as compared to the solution.
  • Bioluminescence data, supported by the survival curves of the animals, showed that S12363-liposomes were able to significantly restrict B16 melanoma progression and increase mice survival.
  • [MeSH-minor] Animals. Area Under Curve. Chemistry, Pharmaceutical. Female. Half-Life. Male. Melanoma, Experimental. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Mice, Nude. Raloxifene Hydrochloride. Tissue Distribution. Vinca Alkaloids

  • Hazardous Substances Data Bank. RALOXIFENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19640257.001).
  • [ISSN] 1532-2394
  • [Journal-full-title] Journal of liposome research
  • [ISO-abbreviation] J Liposome Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Liposomes; 0 / Vinca Alkaloids; 4F86W47BR6 / Raloxifene Hydrochloride
  •  go-up   go-down


70. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, Finkelstein D, Forbes K, Workman CJ, Brown SA, Rehg JE, Jones ML, Ni HT, Artis D, Turk MJ, Vignali DA: IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol; 2010 Dec;11(12):1093-101
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • T(reg) cells induced the generation of iT(R)35 cells in an IL-35- and IL-10-dependent manner in vitro and induced their generation in vivo under inflammatory conditions in intestines infected with Trichuris muris and within the tumor microenvironment (B16 melanoma and MC38 colorectal adenocarcinoma), where they contributed to the regulatory milieu.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2000 May 26;101(5):455-8 [10850488.001]
  • [Cites] Immunol Rev. 2001 Aug;182:5-17 [11722620.001]
  • [Cites] J Exp Med. 2002 Jul 15;196(2):255-60 [12119350.001]
  • [Cites] J Immunol. 2002 Sep 1;169(5):2756-61 [12193750.001]
  • [Cites] J Immunol. 2002 Nov 1;169(9):4712-6 [12391178.001]
  • [Cites] Science. 2003 Feb 14;299(5609):1057-61 [12522256.001]
  • [Cites] Nat Rev Immunol. 2003 Mar;3(3):253-7 [12658273.001]
  • [Cites] Nat Immunol. 2003 Apr;4(4):330-6 [12612578.001]
  • [Cites] J Exp Med. 2003 Dec 15;198(12):1875-86 [14676299.001]
  • [Cites] Semin Immunol. 2004 Apr;16(2):135-43 [15036237.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5450-5 [15100286.001]
  • [Cites] J Exp Med. 2004 Sep 20;200(6):771-82 [15381730.001]
  • [Cites] J Exp Med. 1984 May 1;159(5):1295-311 [6232335.001]
  • [Cites] J Exp Med. 1996 Jul 1;184(1):1-8 [8691122.001]
  • [Cites] Nature. 1997 Oct 16;389(6652):737-42 [9338786.001]
  • [Cites] Immunity. 2005 Mar;22(3):329-41 [15780990.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):263-74 [15776005.001]
  • [Cites] J Immunol. 2005 Sep 1;175(5):3025-32 [16116190.001]
  • [Cites] Nat Rev Immunol. 2006 Apr;6(4):295-307 [16557261.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7276-84 [16849577.001]
  • [Cites] Immunol Rev. 2006 Aug;212:28-50 [16903904.001]
  • [Cites] Immunol Rev. 2006 Aug;212:60-73 [16903906.001]
  • [Cites] Immunol Rev. 2006 Aug;212:256-71 [16903919.001]
  • [Cites] Immunol Rev. 2006 Aug;212:301-13 [16903922.001]
  • [Cites] Immunity. 2006 Aug;25(2):195-201 [16920638.001]
  • [Cites] Nature. 2007 Feb 15;445(7129):771-5 [17220874.001]
  • [Cites] Curr Opin Rheumatol. 2007 May;19(3):252-8 [17414951.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6468-76 [17616708.001]
  • [Cites] Nature. 2007 Nov 22;450(7169):566-9 [18033300.001]
  • [Cites] J Immunol. 2008 Mar 1;180(5):2830-8 [18292504.001]
  • [Cites] Eur J Immunol. 2008 Jul;38(7):1814-21 [18546144.001]
  • [Cites] Nat Immunol. 2008 Sep;9(9):1001-3 [18711438.001]
  • [Cites] J Exp Med. 2008 Sep 1;205(9):1975-81 [18710931.001]
  • [Cites] J Immunol. 2008 Nov 15;181(10):6898-905 [18981109.001]
  • [Cites] Eur J Immunol. 2008 Dec;38(12):3282-9 [19039775.001]
  • [Cites] J Immunol. 2009 Feb 15;182(4):2340-8 [19201888.001]
  • [Cites] J Immunol. 2009 May 15;182(10):6121-8 [19414764.001]
  • [Cites] Blood. 2009 Jun 18;113(25):6392-402 [19377047.001]
  • [Cites] Cancer Res. 2009 Jul 15;69(14):5996-6004 [19567680.001]
  • [Cites] Cell Mol Life Sci. 2009 Aug;66(16):2603-22 [19390784.001]
  • [Cites] J Exp Med. 2009 Aug 3;206(8):1717-25 [19581407.001]
  • [Cites] Am J Respir Crit Care Med. 2009 Nov 1;180(9):823-33 [19679691.001]
  • [CommentIn] Nat Immunol. 2010 Dec;11(12):1077-8 [21079629.001]
  • (PMID = 20953201.001).
  • [ISSN] 1529-2916
  • [Journal-full-title] Nature immunology
  • [ISO-abbreviation] Nat. Immunol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI074878; United States / NIAID NIH HHS / AI / R01 AI039480; United States / NIAID NIH HHS / AI / F32 AI072816; United States / NIAID NIH HHS / AI / R01 AI061570-08; United States / NIAID NIH HHS / AI / R01 AI095466; United States / NIAID NIH HHS / AI / R01 AI091977; None / None / / P30 CA021765-31; United States / NIAID NIH HHS / AI / F32 AI072816-03; United States / NIAID NIH HHS / AI / R01 AI039480-15; United States / NIAID NIH HHS / AI / R01 AI091977-01; United States / NCI NIH HHS / CA / P30 CA023108; United States / NCI NIH HHS / CA / P30 CA021765; United States / NIAID NIH HHS / AI / AI074878-04; United States / NCI NIH HHS / CA / P30 CA021765-31; United States / NIAID NIH HHS / AI / AI061570-08; United States / NIAID NIH HHS / AI / AI072816-03; United States / NIAID NIH HHS / AI / R01 AI074878-04; United States / NIAID NIH HHS / AI / R01 AI061570
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukins; 0 / interleukin-35, human
  • [Other-IDs] NLM/ NIHMS255414; NLM/ PMC3008395
  •  go-up   go-down


71. Arung ET, Kusuma IW, Christy EO, Shimizu K, Kondo R: Evaluation of medicinal plants from Central Kalimantan for antimelanogenesis. J Nat Med; 2009 Oct;63(4):473-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The screening methods used were the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical-scavenging assay, a tyrosinase inhibition assay, and a melanin formation inhibition assay using B16 melanoma cells.
  • The extracts of W. coriacea (bark part of aerial root, 200 microg/ml), Glochidion philippcum (aerial root, 200 and 300 microg/ml), E. palmifolia (bulb, 50 microg/ml), E. zwageri (seed, 100 microg/ml), D. petandra (aerial root, 200 microg/ml), Lansium domesticum (bark, 25 microg/ml), P. foetida (stem, fruit, 300 microg/ml), and Solanum torvum (root, 300 microg/ml) strongly inhibited the melanin production of B16 melanoma cells without significant cytotoxicity.
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Survival. Enzyme Activation / drug effects. Indonesia. Melanoma, Experimental. Mice. Monophenol Monooxygenase / metabolism. Passiflora / chemistry. Solanum / chemistry. Vitex / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oecologia. 2004 Jul;140(2):261-70 [15179575.001]
  • [Cites] Chem Biodivers. 2007 Sep;4(9):2166-71 [17886834.001]
  • [Cites] J Agric Food Chem. 2005 Jul 27;53(15):6105-11 [16029003.001]
  • [Cites] Molecules. 2007 May 15;12(5):1045-56 [17873839.001]
  • [Cites] Biol Pharm Bull. 2006 Sep;29(9):1966-9 [16946519.001]
  • [Cites] Exp Dermatol. 2003 Oct;12(5):655-61 [14705807.001]
  • [Cites] J Agric Food Chem. 2008 Jun 25;56(12):4760-8 [18500813.001]
  • [Cites] J Ethnopharmacol. 2000 Aug;71(3):365-76 [10940572.001]
  • [Cites] J Ethnopharmacol. 2005 Mar 21;97(3):429-39 [15740877.001]
  • [Cites] Biochim Biophys Acta. 1995 Feb 22;1247(1):1-11 [7873577.001]
  • [Cites] J Ethnopharmacol. 2006 Jul 19;106(3):353-9 [16497459.001]
  • [Cites] J Ethnopharmacol. 1999 Aug;66(2):159-65 [10433472.001]
  • [Cites] J Agric Food Chem. 2004 Jan 14;52(1):122-30 [14709024.001]
  • [Cites] Biochem Biophys Res Commun. 2003 May 30;305(2):250-6 [12745066.001]
  • [Cites] Planta Med. 2005 May;71(5):420-3 [15931579.001]
  • [Cites] J Ethnopharmacol. 1998 Sep;62(2):149-65 [9741887.001]
  • [Cites] Chem Pharm Bull (Tokyo). 2006 May;54(5):740-4 [16651782.001]
  • [Cites] Pigment Cell Res. 2003 Dec;16(6):629-38 [14629720.001]
  • [Cites] Gene. 2001 Oct 17;277(1-2):49-62 [11602344.001]
  • [Cites] J Ethnopharmacol. 2008 Aug 13;118(3):522-6 [18602230.001]
  • [Cites] Int J Mol Med. 2009 Feb;23(2):197-204 [19148543.001]
  • [Cites] J Agric Food Chem. 2009 Jan 28;57(2):586-90 [19128040.001]
  • [Cites] Chem Pharm Bull (Tokyo). 2008 Sep;56(9):1314-6 [18758108.001]
  • [Cites] Clin Exp Dermatol. 2001 Oct;26(7):592-9 [11696063.001]
  • [Cites] J Ethnopharmacol. 2004 Dec;95(2-3):277-84 [15507349.001]
  • [Cites] Phytother Res. 2003 Nov;17(9):987-1000 [14595575.001]
  • (PMID = 19618251.001).
  • [ISSN] 1861-0293
  • [Journal-full-title] Journal of natural medicines
  • [ISO-abbreviation] J Nat Med
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Melanins; 0 / Plant Extracts; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


72. Pos Z, Wiener Z, Pocza P, Racz M, Toth S, Darvas Z, Molnar V, Hegyesi H, Falus A: Histamine suppresses fibulin-5 and insulin-like growth factor-II receptor expression in melanoma. Cancer Res; 2008 Mar 15;68(6):1997-2005
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histamine suppresses fibulin-5 and insulin-like growth factor-II receptor expression in melanoma.
  • We previously showed that transgenic enhancement of histamine production in B16-F10 melanomas strongly supports tumor growth in C57BL/6 mice.
  • In the present study, gene expression profiles of transgenic mouse melanomas, secreting different amounts of histamine, were compared by whole genome microarrays.
  • Regulation of histamine-coupled genes was investigated by checking the presence and functional integrity of all four known histamine receptors in experimental melanomas and by administering histamine H1 receptor (H1R) and H2 receptor (H2R) antagonists to tumor-bearing mice.
  • Our results show that histamine enhances melanoma growth via H1R rather than through H2R.
  • On the other hand, we show that engagement of H2R also reduces intracellular protein pools of IGF-IIR and FBLN5, but being a downstream acting posttranslational effect with minimal consequences on exported IGF-IIR and FBLN5 protein levels, H2R is rather irrelevant compared with H1R in melanoma.
  • [MeSH-major] Extracellular Matrix Proteins / biosynthesis. Histamine Release / physiology. Melanoma, Experimental / metabolism. Melanoma, Experimental / secretion. Receptor, IGF Type 2 / biosynthesis. Recombinant Proteins / biosynthesis

  • Hazardous Substances Data Bank. HISTAMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18339882.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Extracellular Matrix Proteins; 0 / Fbln5 protein, mouse; 0 / Histamine Antagonists; 0 / Receptor, IGF Type 2; 0 / Receptors, Histamine; 0 / Recombinant Proteins; 820484N8I3 / Histamine
  •  go-up   go-down


73. Matsuda H, Hirata N, Kawaguchi Y, Yamazaki M, Naruto S, Shibano M, Taniguchi M, Baba K, Kubo M: Melanogenesis stimulation in murine b16 melanoma cells by umberiferae plant extracts and their coumarin constituents. Biol Pharm Bull; 2005 Jul;28(7):1229-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanogenesis stimulation in murine b16 melanoma cells by umberiferae plant extracts and their coumarin constituents.
  • ) CUSSON and C. formosanum YABE, were examined by using cultured murine B16 melanoma cells.
  • The melanogenesis stimulatory effects of sixteen coumarins (1-16) isolated from the seven Umbelliferae crude drugs were also examined.
  • [MeSH-major] Apiaceae / chemistry. Coumarins / pharmacology. Melanins / biosynthesis. Melanoma, Experimental / metabolism. Plant Extracts / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15997104.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Coumarins; 0 / Melanins; 0 / Plant Extracts
  •  go-up   go-down


74. D'Agostini C, Pica F, Febbraro G, Grelli S, Chiavaroli C, Garaci E: Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions. Int Immunopharmacol; 2005 Jul;5(7-8):1205-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions.
  • We report that OM-174, a purified water soluble diphosphorylated and triacetylated lipid A derived from E. coli, is able to reduce tumour progression and to prolong the survival of mice in the B16 melanoma experimental model.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cyclophosphamide / therapeutic use. Lipopolysaccharides / therapeutic use. Melanoma, Experimental / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15914325.001).
  • [ISSN] 1567-5769
  • [Journal-full-title] International immunopharmacology
  • [ISO-abbreviation] Int. Immunopharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Lipopolysaccharides; 8N3DW7272P / Cyclophosphamide; HC3530GGGG / defoslimod
  •  go-up   go-down


75. Jazowiecka-Rakus J, Jarosz M, Kozłowska D, Sochanik A, Szala S: Combination of vasostatin and cyclophosphamide in the therapy of murine melanoma tumors. Acta Biochim Pol; 2007;54(1):125-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of vasostatin and cyclophosphamide in the therapy of murine melanoma tumors.
  • The therapeutic usefulness of such intratumorally delivered recombinant protein was then assessed by investigating its ability to inhibit growth of experimental murine melanomas.
  • In the model of B16-F10 melanoma the MBP/vasostatin construct significantly delayed tumor growth and prolonged survival of treated mice.
  • [MeSH-major] Calreticulin / therapeutic use. Cyclophosphamide / therapeutic use. Melanoma, Experimental / drug therapy. Peptide Fragments / therapeutic use

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17369879.001).
  • [ISSN] 0001-527X
  • [Journal-full-title] Acta biochimica Polonica
  • [ISO-abbreviation] Acta Biochim. Pol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Calreticulin; 0 / Peptide Fragments; 0 / Recombinant Fusion Proteins; 0 / vasostatin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


76. Feng Z, Zhao G, Yu L, Gough D, Howell SB: Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane. Cancer Chemother Pharmacol; 2010 Apr;65(5):923-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Efficacy was quantified by delay in tumor growth of NCI H460 human lung cancer, 2008 human ovarian cancer and B16 melanoma xenografts growing in athymic mice following administration of equitoxic doses of PGG-PTX and Abraxane administered on either a single dose or every 7 day schedule.
  • [MeSH-minor] Albumin-Bound Paclitaxel. Albumins / chemistry. Albumins / therapeutic use. Animals. Carcinoma, Non-Small-Cell Lung / drug therapy. Cell Line, Tumor. Disease Models, Animal. Dose-Response Relationship, Drug. Drug Evaluation, Preclinical. Female. Humans. Lung Neoplasms / drug therapy. Melanoma, Experimental / drug therapy. Mice. Ovarian Neoplasms / drug therapy. Transplantation, Heterologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Drugs. 1996 Aug;7(6):642-8 [8913432.001]
  • [Cites] N Engl J Med. 1995 Apr 13;332(15):1004-14 [7885406.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6D):4269-74 [9494519.001]
  • [Cites] Clin Cancer Res. 1999 Apr;5(4):891-7 [10213226.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4523-31 [15542803.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4136-43 [15930349.001]
  • [Cites] J Pharm Biomed Anal. 2005 Sep 1;39(1-2):170-6 [16085137.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7794-803 [16172456.001]
  • [Cites] Clin Lung Cancer. 2005 Nov;7(3):215-20 [16354318.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1317-24 [16489089.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2248-54 [16609041.001]
  • [Cites] Invest New Drugs. 2007 Aug;25(4):369-75 [17345004.001]
  • [Cites] Br J Cancer. 2008 May 20;98(10):1608-13 [18475293.001]
  • [Cites] J Thorac Oncol. 2008 Jun;3(6):623-30 [18520802.001]
  • [Cites] J Thorac Oncol. 2008 Jul;3(7):728-34 [18594318.001]
  • [Cites] Cancer Chemother Pharmacol. 2010 Feb;65(3):515-26 [19593566.001]
  • [Cites] Adv Exp Med Biol. 2003;519:81-99 [12675210.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2829-34 [10914731.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;46(5):416-22 [11127947.001]
  • [Cites] Eur J Cancer. 2001 Sep;37(13):1590-8 [11527683.001]
  • [Cites] Pharm Res. 2001 Aug;18(8):1157-66 [11587488.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):573-81 [11839679.001]
  • [Cites] Eur J Cancer. 2004 Jan;40(2):291-7 [14728945.001]
  • [Cites] Expert Opin Investig Drugs. 2004 Nov;13(11):1501-8 [15500397.001]
  • [Cites] Cancer Treat Rep. 1987 Jan;71(1):53-9 [2878719.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5877-81 [7903197.001]
  • [Cites] Int J Cancer. 1998 Feb 9;75(4):600-8 [9466663.001]
  • (PMID = 19685054.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Albumin-Bound Paclitaxel; 0 / Albumins; 0 / Antineoplastic Agents; 0 / Proteins; 0 / poly(gamma-glutamylglutamine)paclitaxel; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC2824123
  •  go-up   go-down


77. Wickersheim A, Kerber M, de Miguel LS, Plate KH, Machein MR: Endothelial progenitor cells do not contribute to tumor endothelium in primary and metastatic tumors. Int J Cancer; 2009 Oct 15;125(8):1771-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we studied the differentiation of BM-EPCs and its contribution to tumor vessels in experimental and spontaneous lung metastasis (B16 melanoma and prostate carcinoma), in an autochthonous transgenic model of prostate tumorigenesis, in orthotopically implanted lung tumors [Lewis lung carcinoma (LLC)], in heterotopic subcutaneous models (LLC and C1 prostate carcinoma) growing in green fluorescent protein (GFP)-expressing bone marrow (BM) chimeras.
  • [MeSH-major] Carcinoma, Lewis Lung / pathology. Endothelium, Vascular / pathology. Lung Neoplasms / secondary. Melanoma, Experimental / pathology. Prostatic Neoplasms / pathology. Stem Cells / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19582874.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; 0 / vascular endothelial growth factor A, mouse
  •  go-up   go-down


78. Kashiwagi S, Izumi Y, Gohongi T, Demou ZN, Xu L, Huang PL, Buerk DG, Munn LL, Jain RK, Fukumura D: NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. J Clin Invest; 2005 Jul;115(7):1816-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels.
  • Using intravital microscopy, histological analysis, alpha-smooth muscle actin and chondroitin sulfate proteoglycan 4 staining, microsensor NO measurements, and an NO synthase (NOS) inhibitor, we found that NO mediates mural cell coverage as well as vessel branching and longitudinal extension but not the circumferential growth of blood vessels in B16 murine melanomas.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Physiol Scand. 1992 Jul;145(3):201-27 [1381545.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2002 Jul 1;22(7):1086-92 [12117721.001]
  • [Cites] Cell. 1994 Oct 21;79(2):185-8 [7525076.001]
  • [Cites] J Clin Invest. 1994 Nov;94(5):2036-44 [7525653.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1995 Aug;15(8):1255-61 [7543000.001]
  • [Cites] Microvasc Res. 1996 Jul;52(1):13-26 [8812749.001]
  • [Cites] Cardiovasc Res. 1996 Oct;32(4):687-98 [8915187.001]
  • [Cites] Cell. 1996 Dec 27;87(7):1171-80 [8980224.001]
  • [Cites] Circulation. 1997 Feb 18;95(4):1030-7 [9054767.001]
  • [Cites] Circ Res. 1997 Jun;80(6):845-52 [9168787.001]
  • [Cites] Ann N Y Acad Sci. 1997 Apr 15;811:60-7; discussion 67-9 [9186585.001]
  • [Cites] Science. 1997 Jul 11;277(5323):242-5 [9211853.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):3131-9 [9399960.001]
  • [Cites] Chem Pharm Bull (Tokyo). 1998 Feb;46(2):373-5 [9501473.001]
  • [Cites] Cancer Metastasis Rev. 1998 Mar;17(1):77-89 [9544424.001]
  • [Cites] J Natl Cancer Inst. 1998 Apr 15;90(8):587-96 [9554441.001]
  • [Cites] J Cell Biol. 1998 May 4;141(3):805-14 [9566978.001]
  • [Cites] J Clin Invest. 1998 Jun 1;101(11):2567-78 [9616228.001]
  • [Cites] Nat Med. 1998 Dec;4(12):1371-6 [9846573.001]
  • [Cites] Neuroreport. 1998 Oct 26;9(15):3345-8 [9855277.001]
  • [Cites] Circ Res. 1999 Feb 19;84(3):298-305 [10024303.001]
  • [Cites] Circ Res. 1999 Apr 2;84(6):655-67 [10189353.001]
  • [Cites] Nature. 1999 Jun 10;399(6736):601-5 [10376603.001]
  • [Cites] Am J Pathol. 1999 Oct;155(4):1381-90 [10514420.001]
  • [Cites] J Cardiovasc Pharmacol. 1999 Dec;34(6):879-86 [10598133.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2000 Mar;20(3):659-66 [10712388.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):249-57 [11001068.001]
  • [Cites] Vis Neurosci. 2000 Jul-Aug;17(4):557-66 [11016575.001]
  • [Cites] J Clin Invest. 2000 Oct;106(8):951-61 [11032855.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2604-9 [11226286.001]
  • [Cites] Int J Cancer. 2001 Mar 1;91(5):607-11 [11267968.001]
  • [Cites] J Biol Chem. 2001 Apr 13;276(15):12420-6 [11278407.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3182-7 [11306506.001]
  • [Cites] Curr Top Dev Biol. 2001;52:107-49 [11529428.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Dec;299(3):818-24 [11714864.001]
  • [Cites] Circulation. 2002 Jan 1;105(1):112-7 [11772885.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):985-1000 [11891196.001]
  • [Cites] J Cell Physiol. 2002 Apr;191(1):116-24 [11920687.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):266-76 [12001988.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5301-7 [12235000.001]
  • [Cites] Circ Res. 2002 Dec 13;91(12):e55-64 [12480826.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):522-36 [12492494.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3404-9 [12621153.001]
  • [Cites] Am J Pathol. 2003 Jun;162(6):1927-36 [12759249.001]
  • [Cites] Nat Med. 2003 Jun;9(6):685-93 [12778167.001]
  • [Cites] J Clin Invest. 1992 Mar;89(3):878-82 [1311719.001]
  • [Cites] Am J Physiol. 1999 Oct;277(4 Pt 2):H1600-8 [10516200.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Cancer Cell. 2003 Jul;4(1):31-9 [12892711.001]
  • [Cites] Circ Res. 2003 Oct 31;93(9):e88-97 [14525808.001]
  • [Cites] Cell Tissue Res. 2003 Oct;314(1):15-23 [12883993.001]
  • [Cites] Nature. 2004 Feb 26;427(6977):787 [14985739.001]
  • [Cites] Nature. 2004 Mar 11;428(6979):138-9 [15014486.001]
  • [Cites] Oncologist. 2004;9(2):182-7 [15047922.001]
  • [Cites] Trends Mol Med. 2004 Apr;10(4):143-5 [15162796.001]
  • [Cites] Life Sci. 2004 Jun 25;75(6):639-53 [15172174.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Aug;287(2):L262-8 [15246980.001]
  • [Cites] Nat New Biol. 1973 Apr 4;242(118):148-9 [4512654.001]
  • [Cites] Microvasc Res. 1984 Sep;28(2):206-19 [6094989.001]
  • [Cites] Cancer Res. 1988 May 15;48(10):2641-58 [3282647.001]
  • [Cites] Am J Pathol. 1991 Jun;138(6):1335-47 [1711288.001]
  • [Cites] Cell. 1994 Sep 23;78(6):915-8 [7522969.001]
  • (PMID = 15951843.001).
  • [ISSN] 0021-9738
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01-CA96915; United States / NHLBI NIH HHS / HL / HL-068164; United States / NCI NIH HHS / CA / R24-CA85140; United States / NCI NIH HHS / CA / R24 CA085140; United States / NCI NIH HHS / CA / R01 CA096915; United States / NHLBI NIH HHS / HL / R01 HL068164
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 27JT06E6GR / omega-N-Methylarginine; 31C4KY9ESH / Nitric Oxide; EC 1.14.13.39 / Nitric Oxide Synthase
  • [Other-IDs] NLM/ PMC1143589
  •  go-up   go-down


79. Yang HS, Zhang DM, Deng HX, Peng F, Wei YQ: Antitumor and anti-angiogenesis immunity induced by CR-SEREX-identified Xenopus RHAMM. Cancer Sci; 2010 Apr;101(4):862-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A DNA vaccine based on xRHAMM effectively induced a protective antitumor immunity against local tumor and lung metastasis in B16 melanoma mouse models.
  • Thus, a xenogenic vaccine based on xRHAMM induced an effective immunity against B16 melanoma cells and endothelial cells.
  • [MeSH-major] Antigens, CD44 / immunology. Cancer Vaccines / therapeutic use. Melanoma, Experimental / therapy. Neovascularization, Pathologic / immunology. Vaccines, DNA / therapeutic use

  • Xenbase. Xenbase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20704574.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antigens, Heterophile; 0 / Cancer Vaccines; 0 / Vaccines, DNA
  •  go-up   go-down


80. Posnett DN, Engelhorn ME, Lin Y, Merghoub T, Duan F, Wolchok JD, Houghton AN: Development of effective vaccines for old mice in a tumor model. Vaccine; 2009 Feb 11;27(7):1093-100
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we used DNA tumor antigen vaccines against melanoma and showed that old mice were not protected.
  • However, fusion constructs with Vp22 gave a strong CD4 response to B16 melanoma and the OmpA response is MHC-II dependent.
  • [MeSH-major] Antigens, Neoplasm / immunology. Bacterial Outer Membrane Proteins / immunology. Cancer Vaccines / immunology. Melanoma / prevention & control. Recombinant Fusion Proteins / pharmacology. Vaccines, DNA / immunology. Viral Structural Proteins / pharmacology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19103244.001).
  • [ISSN] 0264-410X
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA033049; United States / NCI NIH HHS / CA / P01 CA033049-250015; United States / NCI NIH HHS / CA / R01 CA056821; United States / NCI NIH HHS / CA / R01 CA056821-16
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antigens, Neoplasm; 0 / Bacterial Outer Membrane Proteins; 0 / Cancer Vaccines; 0 / Recombinant Fusion Proteins; 0 / Vaccines, DNA; 0 / Viral Structural Proteins; 0 / herpes simplex virus type 1 protein VP22; 149024-69-1 / OMPA outer membrane proteins; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ NIHMS95787; NLM/ PMC4229949
  •  go-up   go-down


81. Go S, Sato C, Furuhata K, Kitajima K: Oral ingestion of mannose alters the expression level of deaminoneuraminic acid (KDN) in mouse organs. Glycoconj J; 2006 Jul;23(5-6):411-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We previously demonstrated that free KDN is synthesized de novo from mannose as its precursor sugar in trout testis, and that the amount of intracellular KDN increases in mouse B16 melanoma cells cultured in mannose-rich media [Angata et al. (1999) J. Biol. Chem.
  • [MeSH-minor] Administration, Oral. Animals. Brain / metabolism. Cell Line, Tumor. Culture Media. Female. HeLa Cells. Humans. K562 Cells. Kidney / metabolism. Liver / metabolism. Lung / metabolism. Melanoma, Experimental. Mice. Organ Specificity / drug effects. Spleen / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carbohydr Res. 1989 Jun 1;188:145-55 [2776127.001]
  • [Cites] FEBS Lett. 1992 Feb 17;298(1):39-43 [1371971.001]
  • [Cites] Glycobiology. 1999 Jun;9(6):527-32 [10336984.001]
  • [Cites] Anal Biochem. 1987 Jul;164(1):138-45 [3674364.001]
  • [Cites] Biochim Biophys Acta. 2004 Jul 6;1673(1-2):56-65 [15238249.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Aug 2;261(2):326-31 [10425185.001]
  • [Cites] J Biol Chem. 1991 Nov 15;266(32):21929-35 [1939215.001]
  • [Cites] Eur J Biochem. 2001 Dec;268(24):6473-86 [11737202.001]
  • [Cites] J Clin Invest. 1998 Apr 1;101(7):1414-20 [9525984.001]
  • [Cites] J Biochem. 1984 Jan;95(1):197-203 [6706908.001]
  • [Cites] J Biol Chem. 1993 Feb 5;268(4):2640-8 [8381411.001]
  • [Cites] J Biol Chem. 1996 Apr 19;271(16):9417-21 [8621609.001]
  • [Cites] Pflugers Arch. 2001 Feb;441(5):686-91 [11294251.001]
  • [Cites] Glycoconj J. 2006 Jul;23(5-6):277-90 [16897172.001]
  • [Cites] Glycobiology. 1998 Mar;8(3):277-84 [9451037.001]
  • [Cites] Glycobiology. 2001 Aug;11(8):685-92 [11479279.001]
  • [Cites] J Biol Chem. 1999 Aug 13;274(33):22949-56 [10438460.001]
  • [Cites] Biochimie. 2002 Jul;84(7):655-60 [12453637.001]
  • [Cites] Eur J Biochem. 2002 Dec;269(24):6020-5 [12473097.001]
  • [Cites] J Clin Invest. 1996 Mar 15;97(6):1478-87 [8617881.001]
  • [Cites] Biochim Biophys Acta. 2001 Oct 3;1528(2-3):116-26 [11687298.001]
  • [Cites] J Biol Chem. 1994 Dec 23;269(51):32138-43 [7798209.001]
  • [Cites] Glycobiology. 1998 Mar;8(3):285-95 [9451038.001]
  • [Cites] Biochem Mol Med. 1997 Apr;60(2):127-33 [9169093.001]
  • [Cites] Biochem Biophys Res Commun. 1988 May 31;153(1):172-6 [3377785.001]
  • [Cites] Glycoconj J. 1994 Oct;11(5):493-9 [7696852.001]
  • [Cites] FEBS Lett. 2003 Jan 16;534(1-3):185-9 [12527384.001]
  • [Cites] Chem Rev. 2002 Feb;102(2):439-69 [11841250.001]
  • [Cites] J Biol Chem. 1994 Aug 26;269(34):21415-9 [8063773.001]
  • [Cites] J Biol Chem. 1996 Oct 4;271(40):24341-4 [8798686.001]
  • [Cites] Biochemistry. 2005 Jan 11;44(1):313-20 [15628873.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jul 5;273(2):642-8 [10873658.001]
  • [Cites] Carbohydr Res. 2001 Feb 15;330(3):413-9 [11270821.001]
  • [Cites] Anal Biochem. 1989 May 15;179(1):162-6 [2757191.001]
  • [Cites] J Biol Chem. 1998 Oct 16;273(42):27199-204 [9765240.001]
  • [Cites] J Biol Chem. 1986 Sep 5;261(25):11550-7 [3745155.001]
  • (PMID = 16897182.001).
  • [ISSN] 0282-0080
  • [Journal-full-title] Glycoconjugate journal
  • [ISO-abbreviation] Glycoconj. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media; 0 / Sugar Acids; 22594-61-2 / 3-deoxyglycero-galacto-nonulosonic acid; PHA4727WTP / Mannose
  •  go-up   go-down


82. Dias ML, Carvalho JP, Rodrigues DG, Graziani SR, Maranhão RC: Pharmacokinetics and tumor uptake of a derivatized form of paclitaxel associated to a cholesterol-rich nanoemulsion (LDE) in patients with gynecologic cancers. Cancer Chemother Pharmacol; 2007 Jan;59(1):105-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The association of a derivatized paclitaxel to LDE showed lower toxicity and increased antitumoral activity as tested in a B16 melanoma murine model.
  • LDE concentrates 3.5 times more paclitaxel in malignant tissues than in normal tissues.

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16699792.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Emulsions; 0 / Excipients; 0 / Triglycerides; 97C5T2UQ7J / Cholesterol; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


83. Olszewska-Słonina DM, Styczyński J, Czajkowski R, Drewa TA, Musiałkiewicz D: Cell cycle, melanin contents and apoptosis processes in B16 and Cloudman S91 mouse melanoma cells after exposure to cytostatic drugs. Acta Pol Pharm; 2007 Sep-Oct;64(5):469-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell cycle, melanin contents and apoptosis processes in B16 and Cloudman S91 mouse melanoma cells after exposure to cytostatic drugs.
  • In this work the influence of some cytostatic drugs (at EC50) on melanin content and on the apoptotic processes in mouse melanoma B16 and Cloudman S91 cells in vitro were investigated.
  • The number of viable mouse melanoma B16 and Cloudman S91 cells was estimated by flow cytometry analysis and melanin content in colorimetric assays.
  • The majority of tested cytostatic drugs caused an increase of melanin content in the cells of both melanoma lines, except cisplatin and dacarbazine in the case of B16 cells and dacarbazine in the case of Cloudman S91.
  • Slight increase of melanin content in melanoma cells can be a cell answer to free radicals generation by some cytostatic drugs like adriblastin, actinomycin D and vincristine.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Melanins / analysis. Melanoma, Experimental / drug therapy

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18540169.001).
  • [ISSN] 0001-6837
  • [Journal-full-title] Acta poloniae pharmaceutica
  • [ISO-abbreviation] Acta Pol Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Melanins; 04079A1RDZ / Cytarabine; 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


84. Kushida S, Ohmae H, Kamma H, Totsuka R, Matsumura M, Takeuchi A, Saiki I, Yanagawa T, Onizawa K, Ishii T, Ohn T: Artificial cytokine storm combined with hyperthermia induces significant anti-tumor effect in mice inoculated with lewis lung carcinoma and B16 melanoma cells. Int J Hyperthermia; 2006 Dec;22(8):699-712
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Artificial cytokine storm combined with hyperthermia induces significant anti-tumor effect in mice inoculated with lewis lung carcinoma and B16 melanoma cells.
  • These cytokines in a proper combination augmented the anti-tumor effect of LH and prolonged survival time in Lewis lung carcinoma or B16 melanoma significantly.
  • Moreover, the 12-cytokine cocktail suppressed B 16 metastasis to the lung and lymph nodes, and complete regression of the tumors without regrowth occurred in 3 of 5 mice.
  • In the cured three B16 mice, there was hyperplasia of lymphatic organs with many CD3-positive T lymphocytes.
  • [MeSH-major] Carcinoma, Lewis Lung / therapy. Cytokines / therapeutic use. Hyperthermia, Induced. Immunotherapy, Active / methods. Melanoma, Experimental / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17390999.001).
  • [ISSN] 0265-6736
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


85. Eisenring M, vom Berg J, Kristiansen G, Saller E, Becher B: IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat Immunol; 2010 Nov;11(11):1030-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By systematic analysis of the IL-12-induced immune response to subcutaneous melanoma (B16), we found that tumor suppression was mediated independently of T lymphocytes or NK cells.
  • [MeSH-major] Interleukin-12 / immunology. Lymphoid Tissue / immunology. Melanoma / immunology. Natural Cytotoxicity Triggering Receptor 1 / immunology


86. Sobolewska D, Janeczko Z, Kisiel W, Podolak I, Galanty A, Trojanowska D: Steroidal glycosides from the underground parts of Allium ursinum L. and their cytostatic and antimicrobial activity. Acta Pol Pharm; 2006 May-Jun;63(3):219-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mixture of two steroidal saponins: (25R)-spirost-5-en-3b-ol tetrasaccharide and (25R)-spirost-5, 25(27)-dien-3b-ol tetrasaccharide, along with a 3-hydroxypregna-5,16-dien-20-one glycoside were identified.
  • The results of in vitro cytotoxic activity of the mixture of spirostanol saponins against cell lines melanoma B16 and sarcoma XC and human fibroblasts HSF are also reported.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20085228.001).
  • [ISSN] 0001-6837
  • [Journal-full-title] Acta poloniae pharmaceutica
  • [ISO-abbreviation] Acta Pol Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Cytostatic Agents; 0 / Glycosides; 0 / Steroids
  •  go-up   go-down


87. Wang J, Xie S, Li Y, Guo Y, Ma Y, Zhao J, Phanstiel O 4th, Wang C: Synthesis and evaluation of unsymmetrical polyamine derivatives as antitumor agents. Bioorg Med Chem; 2008 Jul 15;16(14):7005-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A series of unsymmetrically substituted polyamine derivatives were prepared and their cytotoxicities in mouse leukemia L1210, melanoma B16, and HeLa cells were investigated.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18539036.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ornithine Decarboxylase Inhibitors; 0 / Polyamines; 0 / Topoisomerase II Inhibitors; U87FK77H25 / Spermidine
  •  go-up   go-down


88. Dupeyre G, Chabot GG, Thoret S, Cachet X, Seguin J, Guénard D, Tillequin F, Scherman D, Koch M, Michel S: Synthesis and biological evaluation of (3,4,5-trimethoxyphenyl)indol-3-ylmethane derivatives as potential antivascular agents. Bioorg Med Chem; 2006 Jul 1;14(13):4410-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six compounds (20b, 25b-27b, 32b, and 35b) were identified as potent inhibitors of tubulin polymerization and also displayed cytotoxic activities on B16 melanoma cells at a nanomolar level.
  • [MeSH-minor] Animals. Humans. Melanoma, Experimental. Mice. Tubulin / drug effects. Tubulin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16529936.001).
  • [ISSN] 0968-0896
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Stilbenes; 0 / Tubulin; I5590ES2QZ / fosbretabulin
  •  go-up   go-down


89. Kocak E, Lute K, Chang X, May KF Jr, Exten KR, Zhang H, Abdessalam SF, Lehman AM, Jarjoura D, Zheng P, Liu Y: Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res; 2006 Jul 15;66(14):7276-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This notion is supported by a recent clinical trial involving an anti-CTL antigen-4 (CTLA-4) antibody that showed significant clinical responses but severe autoimmune diseases in melanoma patients.
  • The combination of the two antibodies led to CD8 T-cell-mediated rejection of large established MC38 tumors and long-lasting immunity to the same tumor cells, although the same regimen was not effective for B16 melanoma.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16849577.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01CA95426; United States / NCI NIH HHS / CA / R01CA58033; United States / NCI NIH HHS / CA / R01CA69091; United States / NCI NIH HHS / CA / R41CA93107
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, CD137; 0 / Antigens, Differentiation; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human; 0 / Ctla4 protein, mouse; 0 / Receptors, Nerve Growth Factor; 0 / Receptors, Tumor Necrosis Factor; 0 / TNFRSF9 protein, human; 0 / Tnfrsf9 protein, mouse
  •  go-up   go-down


90. Yoon WJ, Kim MJ, Moon JY, Kang HJ, Kim GO, Lee NH, Hyun CG: Effect of palmitoleic acid on melanogenic protein expression in murine b16 melanoma. J Oleo Sci; 2010;59(6):315-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of palmitoleic acid on melanogenic protein expression in murine b16 melanoma.
  • [MeSH-major] Fatty Acids, Monounsaturated / pharmacology. Gene Expression Regulation, Neoplastic / drug effects. Melanins / biosynthesis. Melanoma, Experimental / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20484837.001).
  • [ISSN] 1347-3352
  • [Journal-full-title] Journal of oleo science
  • [ISO-abbreviation] J Oleo Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Fatty Acids, Monounsaturated; 0 / Melanins; 0 / Microphthalmia-Associated Transcription Factor; 209B6YPZ4I / palmitoleic acid; EC 1.- / Oxidoreductases; EC 1.14.18.- / tyrosinase-related protein-1; EC 1.14.18.1 / Monophenol Monooxygenase; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.3.12 / dopachrome isomerase
  •  go-up   go-down


91. Chien AJ, Moore EC, Lonsdorf AS, Kulikauskas RM, Rothberg BG, Berger AJ, Major MB, Hwang ST, Rimm DL, Moon RT: Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A; 2009 Jan 27;106(4):1193-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model.
  • This study demonstrates that in malignant melanoma, elevated levels of nuclear beta-catenin in both primary tumors and metastases correlate with reduced expression of a marker of proliferation and with improved survival, in contrast to colorectal cancer.
  • The reduction in proliferation observed in vivo is recapitulated in B16 murine melanoma cells and in human melanoma cell lines cultured in vitro with either WNT3A or small-molecule activators of beta-catenin signaling.
  • Consistent with these results, B16 melanoma cells expressing WNT3A also exhibit decreased tumor size and decreased metastasis when implanted into mice.
  • Genome-wide transcriptional profiling reveals that WNT3A up-regulates genes implicated in melanocyte differentiation, several of which are down-regulated with melanoma progression.
  • These findings suggest that WNT3A can mediate transcriptional changes in melanoma cells in a manner reminiscent of the known role of Wnt/beta-catenin signaling in normal melanocyte development, thereby altering melanoma cell fate to one that may be less proliferative and potentially less aggressive.
  • Our results may explain the observed loss of nuclear beta-catenin with melanoma progression in human tumors, which could reflect a dysregulation of cellular differentiation through a loss of homeostatic Wnt/beta-catenin signaling.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. ArrayExpress: Data: Microarray .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7328-34 [12499276.001]
  • [Cites] Science. 1999 Sep 17;285(5435):1923-6 [10489374.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 [12781368.001]
  • [Cites] J Cell Biol. 2003 Sep 1;162(5):753-5 [12952929.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3383-8 [12960126.001]
  • [Cites] Dev Cell. 2003 Sep;5(3):367-77 [12967557.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1401-8 [14977843.001]
  • [Cites] Oncogene. 2004 Mar 18;23(12):2264-74 [14755246.001]
  • [Cites] Oncogene. 2004 Jul 1;23(30):5215-26 [15133491.001]
  • [Cites] Pigment Cell Res. 2004 Aug;17(4):318-25 [15250933.001]
  • [Cites] Oncol Rep. 2004 Aug;12(2):245-51 [15254684.001]
  • [Cites] N Engl J Med. 2004 Sep 2;351(10):998-1012 [15342808.001]
  • [Cites] Mod Pathol. 2004 Oct;17(10):1251-8 [15205682.001]
  • [Cites] Nat Rev Genet. 2004 Sep;5(9):691-701 [15372092.001]
  • [Cites] Cell. 1987 Aug 14;50(4):649-57 [3111720.001]
  • [Cites] Genes Dev. 2000 Jan 15;14(2):158-62 [10652270.001]
  • [Cites] Nature. 2000 Aug 3;406(6795):536-40 [10952317.001]
  • [Cites] Jpn J Cancer Res. 2001 Feb;92(2):140-51 [11223543.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):568-76 [11208852.001]
  • [Cites] Int J Cancer. 2001 Jun 15;92(6):839-42 [11351304.001]
  • [Cites] Br J Dermatol. 2001 Aug;145(2):210-6 [11531781.001]
  • [Cites] Mol Cell Biol. 2002 Feb;22(4):1172-83 [11809808.001]
  • [Cites] Melanoma Res. 2002 Apr;12(2):183-6 [11930117.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):279-88 [12086864.001]
  • [Cites] Int J Cancer. 2002 Aug 10;100(5):549-56 [12124804.001]
  • [Cites] Semin Oncol. 2002 Aug;29(4):361-9 [12170439.001]
  • [Cites] J Cell Biol. 2002 Sep 16;158(6):1079-87 [12235125.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1323-7 [12389040.001]
  • [Cites] Cancer. 2002 Dec 15;95(12):2479-86 [12467060.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1790-2 [9065403.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1515-20 [9537257.001]
  • [Cites] J Virol. 1998 Nov;72(11):8463-71 [9765382.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):325-9 [10027390.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9277-80 [10430933.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):3880-2 [10463574.001]
  • [Cites] Cancer Metastasis Rev. 2005 Jun;24(2):237-50 [15986134.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8606-14 [16361544.001]
  • [Cites] Stem Cells. 2006 Jul;24(7):1668-77 [16574754.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7833-6 [16912153.001]
  • [Cites] J Cutan Pathol. 2006 Sep;33(9):599-607 [16965333.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:267-86 [16803431.001]
  • [Cites] Front Biosci. 2007;12:448-57 [17127309.001]
  • [Cites] Science. 2007 Feb 2;315(5812):642-5 [17204608.001]
  • [Cites] Histopathology. 2007 Mar;50(4):453-64 [17448021.001]
  • [Cites] Science. 2007 May 18;316(5827):1043-6 [17510365.001]
  • [Cites] J Biol Chem. 2007 Jun 8;282(23):17259-71 [17426020.001]
  • [Cites] PLoS One. 2007;2(7):e594 [17611626.001]
  • [Cites] Genes Dev. 2007 Nov 15;21(22):2923-35 [18006687.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):949-58 [18398036.001]
  • [Cites] Science. 2008 Apr 18;320(5874):365-9 [18420933.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2890-4 [18539969.001]
  • [Cites] Clin Cancer Res. 2008 Sep 15;14(18):5825-32 [18794093.001]
  • [Cites] Pigment Cell Res. 2003 Jun;16(3):312-7 [12753406.001]
  • (PMID = 19144919.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / Howard Hughes Medical Institute / / ; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / WNT3A protein, human; 0 / Wnt Proteins; 0 / Wnt3 Protein; 0 / Wnt3A Protein; 0 / Wnt3a protein, mouse; 0 / beta Catenin
  • [Other-IDs] NLM/ PMC2626610
  •  go-up   go-down


92. Choi SE, Kim KH, Kwon JH, Kim SB, Kim HW, Lee MW: Cytotoxic activities of diarylheptanoids from Alnus japonica. Arch Pharm Res; 2008 Oct;31(10):1287-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cytotoxic activities of these ten compounds were evaluated against murine B16 melanoma, human SNU-1 gastric cancer, human SNU-354 hepatoma cancer and human SNU-C4 colorectal cell lines.
  • The diarylheptanoids showed potent cytotoxic activities against murine B16 melanoma cells and human SNU-C1 gastric cancer cell when the cell viability was analyzed by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) assay.

  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18958419.001).
  • [ISSN] 0253-6269
  • [Journal-full-title] Archives of pharmacal research
  • [ISO-abbreviation] Arch. Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Diarylheptanoids; 0 / Tetrazolium Salts; 0 / Thiazoles; 298-93-1 / thiazolyl blue
  •  go-up   go-down


93. Bobek V, Kolostova K, Pinterova D, Kacprzak G, Adamiak J, Kolodziej J, Boubelik M, Kubecova M, Hoffman RM: A clinically relevant, syngeneic model of spontaneous, highly metastatic B16 mouse melanoma. Anticancer Res; 2010 Dec;30(12):4799-803
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinically relevant, syngeneic model of spontaneous, highly metastatic B16 mouse melanoma.
  • We report a syngeneic model of spontaneous metastatic B16-F10 mouse melanoma in C57/BL6 mice with a very high metastatic frequency that mimics clinical metastatic melanoma.
  • The B16 melanoma cells were injected between the skin and cartilage on the dorsal side of the ear.
  • The model should be useful to study the mechanism of melanoma metastasis and to develop therapy for this currently untreatable disease.
  • [MeSH-major] Melanoma, Experimental / pathology. Melanoma, Experimental / secondary

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187455.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


94. Ouédraogo M, De Maesschalck E, Soentjens-Werts V, Dubois J: In vitro cytotoxicity study of oxaziridines generated after chlordiazepoxide, demoxepam, and desmethylchlordiazepoxide UV irradiation. Drug Chem Toxicol; 2009;32(4):417-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cytotoxicity of oxaziridines photogenerated after irradiation of chlordiazepoxide (CDZ) and its metabolites was investigated in vitro by a MTT assay on P388 leukemia and B16 melanoma cell lines and compared with that of the anticancer drug, melphalan.
  • [MeSH-minor] Animals. Cell Line. Cell Survival / radiation effects. Drug Screening Assays, Antitumor. Female. Humans. Male. Melanoma, Experimental. Melphalan / adverse effects. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Mice, Inbred DBA. Radiation. Ultraviolet Rays

  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. ETHYLENEIMINE .
  • Hazardous Substances Data Bank. CHLORDIAZEPOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19793035.001).
  • [ISSN] 1525-6014
  • [Journal-full-title] Drug and chemical toxicology
  • [ISO-abbreviation] Drug Chem Toxicol
  • [Language] eng
  • [Publication-type] Clinical Conference; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aziridines; 12794-10-4 / Benzodiazepines; 54P5FEX9FH / aziridine; 6RZ6XEZ3CR / Chlordiazepoxide; 8X1XP5M0SB / demoxepam; Q41OR9510P / Melphalan
  •  go-up   go-down


95. Ramachandran N, Jaroszeski M, Hoff AM: Molecular delivery to cells facilitated by corona ion deposition. IEEE Trans Nanobioscience; 2008 Sep;7(3):233-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Murine B16 melanoma cells were used to demonstrate the molecular delivery of fluorescent dye calcein, the drug bleomycin, and a nucleic acid stain SYTOX-green.
  • [MeSH-major] Biopolymers / chemistry. Biopolymers / pharmacokinetics. Drug Delivery Systems / methods. Electroporation / methods. Melanoma / chemistry. Melanoma / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18779104.001).
  • [ISSN] 1558-2639
  • [Journal-full-title] IEEE transactions on nanobioscience
  • [ISO-abbreviation] IEEE Trans Nanobioscience
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R21 CA106206; United States / NCI NIH HHS / CA / R21CA106206
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biopolymers; 0 / Gases; 0 / Ions
  •  go-up   go-down


96. Zhang X, Hu X, Hou A, Wang H: Inhibitory effect of 2,4,2',4'-tetrahydroxy-3-(3-methyl-2-butenyl)-chalcone on tyrosinase activity and melanin biosynthesis. Biol Pharm Bull; 2009 Jan;32(1):86-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, TMBC effectively inhibited both cellular tyrosinase activity and melanin biosynthesis in B16 melanoma cells without significant cytotoxicity.
  • [MeSH-minor] Animals. Antioxidants / pharmacology. Cell Line, Tumor. Cell Survival / drug effects. Dopamine Agents / pharmacology. Dose-Response Relationship, Drug. Inhibitory Concentration 50. Levodopa / pharmacology. Melanoma, Experimental. Mice. Plant Extracts / chemistry. Plant Extracts / pharmacology. Pyrones / pharmacology. RNA, Messenger / metabolism. alpha-MSH / pharmacology

  • Hazardous Substances Data Bank. KOJIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19122286.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Dopamine Agents; 0 / Melanins; 0 / Plant Extracts; 0 / Pyrones; 0 / RNA, Messenger; 46627O600J / Levodopa; 581-05-5 / alpha-MSH; 5S5A2Q39HX / Chalcone; 6K23F1TT52 / kojic acid; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


97. Nishio S, Yamada N, Ohyama H, Yamanegi K, Nakasho K, Hata M, Nakamura Y, Fukunaga S, Futani H, Yoshiya S, Ueda H, Taniguchi M, Okamura H, Terada N: Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alpha-galactosylceramide and interleukin-18. Cancer Sci; 2008 Jan;99(1):113-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alpha-galactosylceramide and interleukin-18.
  • An injection of NK cell-sensitive mouse B16 melanoma cells into a mouse tail vein produced pulmonary metastasis.
  • The daily administration of alpha-GalCer or IL-18 alone for 4 days starting 1 day after the injection of B16 melanoma cells markedly suppressed the number of pulmonary metastatic foci, and their combined administration enhanced the antitumor effect compared with single administration.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Melanoma, Experimental / drug therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17949451.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 2-amino-1-galactopyranosyloxy-3,4-dihydroxyoctadecane; 0 / Cytokines; 0 / Galactosylceramides; 0 / Interleukin-15; 0 / Interleukin-18
  •  go-up   go-down


98. Tejeda M, Gaal D, Hullán L, Csuka O, Schwab R, Szokoloczi O, Kéri GY: Continuous administration of the somatostatin structural derivative /TT-232/ by subcutaneously implanted osmotic pump improves the efficacy and potency of antitumor therapy in different mouse and human tumor models. Anticancer Res; 2008 Sep-Oct;28(5A):2769-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • -inserted Alzet osmotic minipump, and on different types of transplantable rodent (S-180 sarcoma, P-388sc lymphoid leukemia, Colon-26 adenocarcinoma, MXT breast carcinoma, B-16 melanoma) and human tumor models (HT-18 lymphoid melanoma, T-47/D breast carcinoma, A-431 epidermoid carcinoma).
  • In the B-16 melanoma model, the infusion treatments resulted in 47% -63% growth inhibition.
  • The tumor growth inhibitory effect of infusion treatment with TT-232 on HT-18 human lymphoid melanoma tumor proved to be significant, resulting in 69%-79% decreases in tumor volume.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19035308.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Peptides, Cyclic; 0 / TT2-32; 51110-01-1 / Somatostatin
  •  go-up   go-down


99. Duan F, Lin Y, Liu C, Engelhorn ME, Cohen AD, Curran M, Sakaguchi S, Merghoub T, Terzulli S, Wolchok JD, Houghton AN: Immune rejection of mouse tumors expressing mutated self. Cancer Res; 2009 Apr 15;69(8):3545-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To address these questions, a mutated self-antigen, designated tyrosinase-related protein 1 (Tyrp1)-WM, derived from Tyrp1 was expressed in the poorly immunogenic, spontaneously arising B16 melanoma and the immunogenic, chemically induced LiHa fibrosarcoma.
  • B16 melanomas expressing Tyrp1-WM induced minimal T-cell responses, and no tumor immunity was detected.
  • These results show that B16 tumors expressing mutations that generate strongly immunogenic epitopes naturally induce T-cell responses, which are insufficient to reject tumors.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Immunol. 2004 Mar;34(3):613-22 [14991590.001]
  • [Cites] J Exp Med. 1998 Nov 2;188(9):1553-61 [9802967.001]
  • [Cites] J Immunol. 2004 Jun 15;172(12):7306-14 [15187106.001]
  • [Cites] Immunogenetics. 2004 Sep;56(6):405-19 [15349703.001]
  • [Cites] J Exp Med. 2004 Sep 20;200(6):771-82 [15381730.001]
  • [Cites] J Immunol. 2004 Oct 15;173(8):5008-20 [15470044.001]
  • [Cites] Br J Cancer. 1976 Mar;33(3):241-59 [773395.001]
  • [Cites] J Exp Med. 1984 May 1;159(5):1295-311 [6232335.001]
  • [Cites] Cell. 1989 Jul 28;58(2):293-303 [2568889.001]
  • [Cites] J Exp Med. 1990 Apr 1;171(4):1375-80 [2324688.001]
  • [Cites] Exp Cell Res. 1991 Oct;196(2):233-40 [1832641.001]
  • [Cites] Nature. 1994 May 5;369(6475):67-71 [8164742.001]
  • [Cites] J Exp Med. 1994 Nov 1;180(5):1599-607 [7964448.001]
  • [Cites] J Clin Invest. 1998 Sep 15;102(6):1258-64 [9739060.001]
  • [Cites] J Invest Dermatol. 1998 Apr;110(4):324-31 [9540969.001]
  • [Cites] Eur J Immunol. 1999 Feb;29(2):592-601 [10064075.001]
  • [Cites] J Exp Med. 2005 Oct 3;202(7):885-91 [16186187.001]
  • [Cites] Nat Med. 2006 Feb;12(2):198-206 [16444264.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4904-12 [16651447.001]
  • [Cites] J Clin Invest. 2006 May;116(5):1382-90 [16614758.001]
  • [Cites] J Immunol. 2006 Jun 1;176(11):6434-42 [16709800.001]
  • [Cites] J Clin Invest. 2006 Oct;116(10):2587-90 [17016554.001]
  • [Cites] J Clin Invest. 2006 Oct;116(10):2777-90 [17016559.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18238-42 [17108085.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18033-4 [17116890.001]
  • [Cites] Nature. 2007 Mar 8;446(7132):153-8 [17344846.001]
  • [Cites] Cancer Res. 2008 Feb 1;68(3):889-92 [18245491.001]
  • [Cites] J Exp Med. 1999 Dec 6;190(11):1717-22 [10587362.001]
  • [Cites] Immunity. 2000 Oct;13(4):529-38 [11070171.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4078-83 [11358829.001]
  • [Cites] Nat Immunol. 2002 Feb;3(2):135-42 [11812990.001]
  • [Cites] Immunity. 2002 Feb;16(2):311-23 [11869690.001]
  • [Cites] J Mol Biol. 2003 Feb 28;326(4):1157-74 [12589760.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15059-64 [14608036.001]
  • [Cites] Adv Cancer Res. 2003;90:157-77 [14710950.001]
  • [Cites] Immunity. 1995 Jan;2(1):45-59 [7600302.001]
  • [Cites] J Invest Dermatol. 1995 Jul;105(1):113-9 [7615964.001]
  • [Cites] Science. 1995 Sep 1;269(5228):1281-4 [7652577.001]
  • [Cites] Cell. 1996 Apr 5;85(1):27-37 [8620534.001]
  • [Cites] J Exp Med. 1997 Feb 17;185(4):695-705 [9034148.001]
  • [Cites] Int J Cancer. 1997 Jun 11;71(6):932-6 [9185691.001]
  • [Cites] J Invest Dermatol. 1997 Dec;109(6):788-95 [9406822.001]
  • [Cites] J Immunol. 2004 May 15;172(10):5823-7 [15128759.001]
  • (PMID = 19351857.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] None / None / / R01 CA056821-16; United States / NCI NIH HHS / CA / P01 CA033049-24; United States / NCI NIH HHS / CA / R01 CA056821-16; United States / NCI NIH HHS / CA / CA033049-24; United States / NCI NIH HHS / CA / P01 CA033049; United States / NCI NIH HHS / CA / R01 CA56821; United States / NCI NIH HHS / CA / P01 CA059350; United States / NCI NIH HHS / CA / R01 CA056821; United States / NCI NIH HHS / CA / P01 CA59350; United States / NCI NIH HHS / CA / P01 CA33049
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantigens; 0 / Epitopes, T-Lymphocyte; 0 / Membrane Glycoproteins; EC 1.- / Oxidoreductases; EC 1.14.18.- / Tyrp1 protein, mouse
  • [Other-IDs] NLM/ NIHMS117220; NLM/ PMC2767208
  •  go-up   go-down


100. Kanwar JR, Palmano KP, Sun X, Kanwar RK, Gupta R, Haggarty N, Rowan A, Ram S, Krissansen GW: 'Iron-saturated' lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy. Immunol Cell Biol; 2008 Mar-Apr;86(3):277-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lf(+)-fed mice bearing either EL-4, Lewis lung carcinoma or B16 melanoma tumours completely rejected their tumours within 3 weeks following a single injection of either paclitaxel, doxorubicin, epirubicin or fluorouracil, whereas mice fed the control diet were resistant to chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Lewis Lung / drug therapy. Lactoferrin / administration & dosage. Lymphoma / drug therapy. Melanoma, Experimental / drug therapy

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18268518.001).
  • [ISSN] 0818-9641
  • [Journal-full-title] Immunology and cell biology
  • [ISO-abbreviation] Immunol. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Adjuvants, Pharmaceutic; E1UOL152H7 / Iron; EC 3.4.21.- / Lactoferrin
  •  go-up   go-down






Advertisement